Sleep & fitness
focus report

Anxiety genetics does not mean personality judgment. The practical version is stress-system context: threat sensitivity, sleep disruption, caffeine response, alcohol rebound, workload, avoidance, rumination, panic symptoms, and how quickly the body comes back down after pressure.

Sample Customer's anxiety-disorder score is in the >90% category. That is a strong signal, but it is not the same as saying "you are anxious." If anxiety, tension, avoidance, panic, or high stress-load patterns are present, this is one of the findings that makes tracking them worthwhile.

A good biological hook: recent anxiety large studies points toward GABAergic inhibition, the brain's brake system. That makes the trait feel less vague, but it still remains a many tiny genetic nudges susceptibility finding, not a diagnosis.

For this sample, the useful next layer is a two-week log of sleep, caffeine, alcohol, exercise, stress load, panic symptoms, avoidance, and function.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

Alcohol-dependence genetics needs a careful tone. The useful point is not "an addiction gene". The useful point is that metabolism, reward, stress response, family history, environment, trauma, sleep, and social setting can all make alcohol risk feel very different from person to person.

Sample Customer's score is in the >90% category, so this needs a careful tone. It is not a label about identity, willpower, or current drinking. If alcohol ever feels hard to control, causes harm, or runs strongly in the family, the useful next step is a private, practical conversation with a doctor rather than trying to interpret DNA alone.

A useful balance: alcohol-use disorder heritability is often estimated around 40-60%, but the outcome is not inevitable. Protective metabolism variants such as ALDH2 also show how genetics can reduce drinking by making alcohol physically aversive.

For this sample, this is a support-and-measurement finding. The right interpretation depends on current drinking pattern, cravings, loss of control, withdrawal symptoms, family history, sleep, mood, liver markers, triglycerides, medicines, and whether help is wanted or needed.

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

CYP1A2 is the everyday medication-response genetics story: the same coffee can feel like a gentle nudge for one person and an all-day stimulant for someone else. CYP1A2 mainly changes how quickly caffeine is cleared, while other genes and tolerance shape how caffeine feels.

For this sample, this is a faster caffeine-processing marker. Faster clearance may make caffeine wear off sooner, but it does not prove caffeine is helpful, harmless, or irrelevant.

A useful mental model: caffeine peaks quickly, then the tail depends on metabolism, timing, smoking, pregnancy status, medications, liver context, and receptor tolerance. The useful next step is to avoid the simplistic "fast processor = drink more" framing.

For this sample, if caffeine is a real part of daily life, the practical check is simple: dose, last-cup timing, sleep latency, night waking, anxiety, palpitations, reflux, headaches, blood pressure, and stimulant or interacting medication context.

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

Osteoporosis genetics is useful because bone is measurable and modifiable. Bone is not passive scaffolding; it responds to loading, hormones, muscle, nutrition, vitamin D status, medications, age, falls risk, and family history.

Sample Customer's osteoporosis score is around the 90th percentile, making it one of the more active movement/bone findings. It is a good "do something sensible early" finding because the practical levers are clear: resistance training, impact/loading where appropriate, protein, vitamin D/calcium context, fracture history, family history, steroid exposure, and DEXA eligibility.

The best angle here: bone and muscle are one system. Muscle talks to bone, bone talks back through endocrine signals, and loading exercise affects the whole network. That makes the finding feel more active and less like an elderly-fracture warning.

For this sample, the useful point is to connect the score to real context: fractures, family history, training load, steroid exposure, vitamin D, calcium intake, and whether a DEXA scan is appropriate.

At 37, this is a good time to lay foundations for stronger bone health later: progressive strength, safe impact or loading, protein, vitamin D and calcium adequacy, and avoiding long inactive spells matter before this becomes a fracture-risk decision.

Fatigue is one of the most human traits here, but also one of the easiest to overclaim. It can come from sleep, iron status, thyroid, infection, mood, glucose swings, overtraining, alcohol, medications, pain, inflammation, automatic nervous-system issues, or a post-viral state. Genetics may lower the threshold, but the lived cause is usually a stack.

Sample Customer's fatigue score is around the 85th percentile, so it is worth noticing. The surrounding results make the pattern more interesting: insomnia, snoring, restless legs, chronic pain, and tinnitus all look relatively quiet; heart-rate variability and resting heart rate look favourable; vitamin D looks favourable; hypothyroidism is very low. But serum iron is low, HbA1c/type 2 diabetes genetics are high, sleep duration and chronotype are distinctive, and tryptophan/serotonin signals are unusual enough to add colour rather than answers.

A useful way to explain this is the emerging genetics of ME/CFS and post-trigger fatigue. That pushes back against the lazy idea that chronic fatigue is purely psychological. For this sample, though, this is not an ME/CFS claim. It is a reason to check the reversible basics carefully if fatigue is actually present.

For this sample, Full blood count, ferritin with transferrin saturation, B12/folate, thyroid markers, vitamin D, HbA1c/glucose, sleep quality, training load, alcohol pattern, mood, and medication/supplement review are more useful than trying to "optimise fatigue genes."

At 37, this is a good time to lay foundations for stronger bone health later: progressive strength, safe impact or loading, protein, vitamin D and calcium adequacy, and avoiding long inactive spells matter before this becomes a fracture-risk decision.

ADHD genetics works best as executive-function context rather than a fixed identity label. The relevant everyday questions are structure, distraction, task switching, time blindness, restlessness, sleep timing, caffeine timing, workload design, emotional load, and whether childhood history or current impairment fits.

Sample Customer's ADHD score is around the 79th percentile. That is higher, but not a diagnosis. It is most useful beside anxiety at >90% and faster reaction time at 11th, because attention, stress, processing speed, and fatigue can blur together in real life.

A strong point: ADHD is highly heritable and overlaps genetically with broader self-regulation and externalising traits. That does not mean every high-score person has ADHD; it means the useful question is better questions about function.

For this sample, if symptoms matter, the useful route is structured tracking: sleep consistency, caffeine timing, work blocks, distraction pattern, task initiation, anxiety/mood symptoms, childhood history, and practical accommodations.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

Depression genetics does not mean a verdict about mood. The practical version is vulnerability context: sleep, anhedonia, energy, appetite, social withdrawal, stress load, alcohol, medication effects, inflammation, life events, and whether symptoms are persistent or situational.

Sample Customer's depression score is around the 78th percentile. That is a higher inherited-tendency signal, but it is not the same thing as having depression. The practical version is practical: if mood, fatigue, motivation, enjoyment, sleep, alcohol, medicines, or life stress are part of the real-world picture, this finding helps explain why they are worth taking seriously.

A useful debate: the old "chemical imbalance" story was too simple, but that does not mean depression is not biological or that treatments do not work. The modern picture is circuits, stress response, sleep, inflammation, plasticity, genetics, and environment.

For this sample, the practical version is a two-week pattern check: mood duration, enjoyment, sleep, appetite, activity, social contact, alcohol, medicines, life stress, and any safety concern. If none of that is present, this stays as background rather than a label.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

Asthma is not one disease shape. It can be allergic, exercise-triggered, infection-triggered, adult-onset, eosinophilic, obesity-linked, reflux-adjacent, or mixed. That heterogeneity is why genetics can feel slippery: a broad asthma score is really aggregating several airway-reactivity routes.

Sample Customer's asthma score is around the 75th percentile, which is higher but not as loud as allergic rhinitis. The pair matters. A very high rhinitis signal plus a higher asthma signal makes the nose-airway connection worth checking if there is cough, wheeze, chest tightness, exercise limitation, or nighttime symptoms.

A better asthma story is the airway as a living barrier, not just a tube. In allergic or "type 2" asthma, the immune system, airway lining, mucus, and tiny airway muscles can all become too reactive. That is why the useful questions are concrete: wheeze, cough after exercise, chest tightness at night, cold-air triggers, dust or pet triggers, and whether nose symptoms make breathing worse.

For this sample, the useful link is allergic rhinitis plus breathing comfort: uncontrolled nasal allergy can worsen sleep and airway comfort even when someone does not think of themselves as "asthmatic."

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

VO2max is the oxygen-delivery-and-use score: heart, lungs, blood, capillaries, mitochondria, and muscle all working together. It is one of the most useful movement traits because it is measurable, trainable, and strongly linked to healthspan discussions.

Sample Customer's VO2max score is around the 18th percentile, so this is a lower inherited aerobic-capacity signal. That does not mean low ability. It can be written as a clear experiment: if aerobic fitness matters, measure baseline and train it.

The most useful story is the Attia-style longevity framing: VO2max often behaves like a powerful whole-body capacity marker. The useful point is to keep the energy of that point without overclaiming exact mortality rankings from public posts.

For this sample, it pairs well with the positive lean-mass/bone-density story: the strength base looks useful, while aerobic capacity may need the more deliberate programme.

At 37, this is a good time to lay foundations for stronger bone health later: progressive strength, safe impact or loading, protein, vitamin D and calcium adequacy, and avoiding long inactive spells matter before this becomes a fracture-risk decision.

IBS is a functional gut pattern: abdominal pain or discomfort with altered bowel habits, without the visible inflammatory damage that defines IBD. That does not make it imaginary. Motility, gut sensitivity, gut-brain signalling, serotonin routes, gut-microbe output, stress physiology, sleep, and food fermentation can all be involved.

Sample Customer's IBS score sits in the >90% category, making it one of the clearest gut-pattern signals here. That deserves attention if there are symptoms, but it is not a diagnosis. The useful move is to separate functional gut symptoms from inflammatory red flags, and to avoid jumping straight to broad restriction diets or alarm.

The most useful modern IBS framing is that it is not one thing. Some people look more fermentation-led, some more constipation/methane-led, some more bile-acid or motility-led, and some more gut-brain or pain-threshold-led. Gas patterns, bile-acid handling, transit speed, mast-cell behaviour, and extra-sensitive gut nerves can all change what actually helps.

For this sample, a two-week log of pain, stool form, urgency, bloating, reflux, night symptoms, blood or mucus, food timing, alcohol, painkiller or acid-suppressor exposure, antibiotics, sleep, and stress would be more useful than guessing from DNA alone. If symptoms are active, the interesting next questions are pattern questions: diarrhea-leaning, constipation-leaning, mixed, post-infectious onset, bloating after fermentable foods, bile-acid diarrhea, food-fermentation triggers, or visceral-pain sensitivity.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

LDL cholesterol measures how much cholesterol is being carried inside LDL particles. It is not the same as ApoB, which counts the particles, but it is still one of the most important heart-risk markers to know.

Sample Customer's LDL cholesterol score is in the >90% category, making it one of the strongest results overall. What makes it especially persuasive is the company it keeps: ApoB is 78th and triglycerides are 77th. At the same time, total cholesterol is low at 13th and Lp(a) is near-median, so the story is specific rather than generic. This is not "all lipid genetics are high"; it is a focused LDL/ApoB/remnant pattern.

The useful debate is straightforward. LDL-C is practical and well tested, while ApoB gives the cleaner particle count. In Sample Customer's case, both matter: the LDL result is very high, and ApoB is elevated enough that the particle-count check becomes one of the most useful next measurements.

For this sample, the right next question is simple: what are measured LDL-C, ApoB, non-HDL-C, triglycerides, and Lp(a) in blood?

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

Type 2 diabetes is one of the clearest examples of genetic risk that is real but highly modifiable. The newer research is more interesting than a single "diabetes risk" score: very large studies, including work across roughly 2.5 million people, can cluster DNA signals into routes such as beta-cell function, insulin resistance, obesity-linked biology, and complication risk.

Sample Customer's score is in the >90% category, and it sits beside high HbA1c, triglycerides, LDL cholesterol, ApoB, and a detected TCF7L2 signal. That makes this less like one isolated disease label and more like a metabolic cluster: glucose handling, insulin secretion, lipid particles, and long-term vascular risk are all worth checking as a system.

One useful insight is that diabetes genetics is not one single thing. Some inherited patterns lean more toward insulin resistance, some toward beta-cell function, some toward body-fat distribution, and some toward complication risk. For this sample, the more useful question is not just "is diabetes genetics higher?" but "which part of the metabolic machinery should be measured first?"

For this sample, the practical reading is: measure early and do not let the label do all the work. HbA1c, fasting glucose, fasting insulin, OGTT, and CGM can each reveal different things. Muscle, aerobic fitness, sleep, visceral fat, and food pattern are the levers that decide whether this DNA signal becomes visible.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

Allergic rhinitis is the hay-fever and indoor-allergen finding: pollen, dust mites, mould, pets, congestion, sneezing, itchy eyes, post-nasal drip, sleep disruption, and that feeling of being low-level inflamed by the air. It also sits inside the broader atopic pattern with asthma and eczema.

Sample Customer's allergic rhinitis score is in the >90% category, making it one of the strongest immune/allergy findings here. This is not miscellaneous background. It is a highly recognisable daily-life signal if symptoms match.

The strongest practical story is the atopic-march idea: rhinitis, asthma, and eczema share genetic and immune architecture, but environment decides how and when the tendency shows up. That makes the finding practical rather than abstract. It invites questions about seasonality, bedrooms, pets, mould, exercise, sleep, and airway symptoms.

For this sample, the useful action is not genetic alarm; it is matching pattern to reality: triggers, timing, antihistamine response, nasal steroid response, sleep quality, wheeze, cough, and eye symptoms.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

HbA1c is both a glucose marker and a measurement instrument. It estimates average glucose exposure over the last few months by measuring how much glucose has attached to hemoglobin in red blood cells. That is why it is so useful, but also why it can be distorted by iron status, B12, anaemia, hemoglobin variants, red-cell lifespan, kidney disease, and ancestry-linked variants.

Sample Customer's HbA1c score is in the >90% category, which is one of the louder results here. Because type 2 diabetes is also high, it does not look random or isolated. It fits the wider glucose-and-metabolism pattern, especially alongside triglycerides and ApoB.

The most interesting detail is that HbA1c can rise for two different reasons. Sometimes average glucose really is higher. Sometimes red blood cells change how the test reads. That is more honest than simply saying "your average blood sugar may be higher."

For this sample, this is a clear measurement note. HbA1c, fasting glucose, fasting insulin, an oral glucose test, fructosamine/glycated albumin, or even a short glucose-monitor experiment can separate real glucose handling from test noise. The DNA result is high enough that checking is more useful than guessing.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

Antidepressant medication-response genetics is not a "which medication will make you feel better" oracle. Its strongest use is more modest and practical: it can help explain exposure, side effects, and dose questions for specific medicines processed by CYP2C19, CYP2D6, or CYP2B6.

For this sample, this is faster citalopram, escitalopram, and sertraline processing context, and it is best kept as medicine-specific medication-response genetics. That means it is not a mental-health trait or a general antidepressant recommendation.

A useful balance: SSRI response is in practice complex, but CYP status can still matter for blood levels and tolerability. Faster metabolism can sometimes mean lower exposure at standard doses, depending on the drug.

For this sample, if selected SSRI or serotonin-reuptake antidepressant prescribing is relevant, include current medicines, dose, indication, response, side effects, past trials, and medication review.

At 37, keep this for medication moments: it matters when a relevant prescription is being considered, not as an everyday diagnosis.

Tricyclic antidepressants are old drugs with real utility and a real side-effect burden. They can be used for depression, neuropathic pain, migraine prevention, sleep, and other indications, but the dose-response window can be narrower than people expect.

For this sample, the genetic result points to faster metabolism for selected tricyclic antidepressants. That makes it a medication-response note for future prescribing or review, not a mental-health trait or a treatment recommendation.

The useful "old drug, modern dosing" story: CYP2D6 and CYP2C19 can make a standard TCA dose too high for some people or too low for others. Faster metabolism can point toward lower exposure or reduced effect for certain TCAs, depending on the drug and route.

For this sample, if a TCA is ever considered, include indication, dose, current medicines, side effects, ECG/cardiac risk where relevant, blood-level monitoring if available, and medication review.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

CYP2C19 is one of the useful "same pill, different exposure" genes. For proton-pump inhibitors such as omeprazole, lansoprazole, and pantoprazole, faster metabolism can mean lower exposure and potentially less acid suppression at a standard dose.

For this sample, this is a faster PPI processing marker, and it is best kept as medicine-specific medication-response genetics. That means it is not a general gut-health finding. It matters only if a PPI is being used, considered, failing, causing side effects, or interacting with another medicine.

A useful angle is context flip: slower CYP2C19 metabolism can sometimes help PPI efficacy, such as H. pylori eradication, while being risky for drug interactions in other contexts. Faster metabolism is the opposite kind of question: is the standard dose enough?

For this sample, if omeprazole, lansoprazole, pantoprazole, clopidogrel, or other CYP2C19 substrates are relevant, include the medicine, dose, indication, response, side effects, and medication review.

At 37, keep this for medication moments: it matters when a relevant prescription is being considered, not as an everyday diagnosis.

FTO is the famous "obesity gene," although that nickname oversells it. The common rs9939609 signal is linked to appetite, food intake, satiety, and higher-calorie preference more than to some mysterious inability to burn energy. The often-cited effect size is modest: two risk DNA versions have been associated with roughly 3 kg higher body weight and around 1.6-1.7x higher obesity likelihood in older studies.

Sample Customer has the tracked FTO background marker detected, but the broader BMI many tiny DNA score is only around the 34th percentile. That is the important balance. This is not a "your weight genetics are high" result. It is one recognisable appetite-related marker in the background, while the overall inherited BMI tendency looks relatively calm.

The interesting part of FTO is gene-environment interaction. The effect appears much larger in environments that make overeating easy and activity optional, and much smaller in people with consistent physical activity, sleep, protein/fiber-forward meals, and a less chaotic food environment. So this marker is works best as appetite-context colour, not as a main health risk.

For this sample, it also helps explain why the metabolic cluster is bigger than body weight. The type 2 diabetes/HbA1c/lipid signals are loud even though BMI genetics are not. That makes metabolic measurement more important than assumptions based on size.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

Statin muscle symptoms are not one thing. They range from vague aches to rare severe muscle injury, and the cause can be dose, drug interactions, exercise load, thyroid status, kidney or liver context, nocebo effects, or genetics.

For this sample, this is reduced CYP2C9 metabolism for selected statins, and it is best kept as medicine-specific medication-response genetics. That means it is not a general muscle trait or a reason to avoid lipid-lowering treatment.

A useful management angle: statin intolerance is often handled by changing statin type, dose, schedule, or adding non-statin options, not by giving up on LDL/ApoB risk. Genetics can help explain why one statin is harder to tolerate than another.

For this sample, it is especially worth carrying forward because Sample Customer's LDL and non-HDL signals are strong. If statins are considered or muscle symptoms occur, include statin name, dose, symptoms, CK if indicated, kidney/liver/thyroid context, interacting medicines, LDL/ApoB risk, and medical review.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

FUT2 is a strange little bridge between blood markers, gut biology, and B12 interpretation. The famous rs601338 DNA difference affects secretor status: whether certain blood-group-related sugars are expressed in secretions and on gut surfaces. That can shape gut microbes and infection patterns, and it also shows up in vitamin B12 genetic studies.

Sample Customer has the tracked FUT2 B12-background marker detected. This does not mean "B12 deficiency" by itself. Some studies suggest that non-secretor status can be associated with higher circulating B12 in some studies, likely through B12-binding proteins such as haptocorrin rather than simple absorption. That is why this is interpretation context, not a diagnosis.

For this sample, the usefulness is conditional: if fatigue, neuropathy symptoms, diet pattern, metformin/PPI use, gut history, or unusual blood-count markers make B12 relevant, then measured B12 works best with functional B12 markers such as MMA or homocysteine where appropriate. Otherwise, this is interesting biology rather than a main concern.

For this sample, it sits beside favourable B12 genetics, folate near typical/favourable, and a higher fatigue tendency. It is useful context, but not a main finding.

At 37, sleep and recovery habits can protect training capacity, mood, and metabolic flexibility before tiredness or schedule strain becomes a fixed pattern.

TCF7L2 rs7903146 is one of the classic common variant findings in type 2 diabetes genetics. It has been replicated for years and is especially interesting because it points more toward beta-cell function and insulin secretion than simply "weight" or "lifestyle."

Sample Customer has the tracked TCF7L2 background marker detected. On its own, that would be a useful context note. Here, it matters more because the broader type 2 diabetes DNA result is also >90th and HbA1c is >90th. The single-marker and many tiny genetic nudges layers are pointing in the same general direction.

The useful insight is that not all diabetes risk is the same. Some people are more loaded toward insulin resistance; others toward beta-cell capacity or secretion. TCF7L2 is a reminder that glucose control is partly about how well the pancreas can respond, not only about body size.

For this sample, this supports a more careful glucose follow-up stack: not just fasting glucose, which is fairly calm genetically here, but HbA1c, fasting insulin, OGTT, and possibly CGM if the goal is to understand post-meal handling and insulin demand.

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

Albuminuria sounds niche until you realise what it is measuring: tiny amounts of albumin leaking into urine. Clinicians often treat it as an early kidney-filter stress signal, but the more interesting framing is broader than kidney alone. urine albumin-to-creatinine ratio can act like a vascular-blood-vessel lining stress marker, sometimes moving before eGFR or creatinine look concerning.

Sample Customer's albuminuria score is around the 89th percentile, which makes this one of the more concrete liver/kidney findings here. It does not mean there is albumin in the urine now. It means this is a good trait to convert from DNA context into a simple measured check: urine albumin-to-creatinine ratio, ideally repeated if abnormal.

The useful angle is measurement quirks rather than vague risk language. A spot urine albumin-to-creatinine ratio is practical, but it can be distorted by recent hard exercise, illness, UTI, menstruation, and changes in urine creatinine. That makes confirmation important. One clean measurement is informative; one noisy measurement is not a personality trait.

For this sample, this is a high-value note because it is both early and measurable. It also connects neatly to the type 2 diabetes/HbA1c and blood-pressure areas: glucose, BP, weight, smoking, and kidney-protective medication context all matter if the biomarker is actually elevated.

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

Migraine is not just a bad headache. It is a nervous-system excitability pattern that can involve pain, sensory sensitivity, aura, nausea, light sensitivity, sleep disruption, hormones, stress, exertion, hydration, caffeine, and food timing.

Sample Customer's migraine score is around the 85th percentile, so this is an active movement/pain finding. It can be treated as a trigger-pattern finding, not a diagnosis. The useful question is whether there are headache days, aura, neurologic symptoms, acute-medication days, or repeatable triggers.

A useful excitability angle: migraine genetics often points toward ion channels, sensory processing, and inhibitory/excitatory balance. That links neatly with Sample Customer's higher glutamate and anxiety/stress context without claiming a single way it works.

For this sample, a simple migraine diary would be more useful than guessing from the percentile: sleep, caffeine, alcohol, skipped meals, hydration, stress, exertion, screen/light exposure, and symptom timing.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

ApoB is one of the most useful cholesterol ideas because it turns "cholesterol" from a vague substance into a traffic count. Each artery-risk particle usually carries one ApoB molecule, so ApoB is roughly a count of how many of those particles are moving through the bloodstream.

Sample Customer's ApoB score is around the 78th percentile. That is not as extreme as LDL cholesterol, but it is high enough to matter because the neighbouring results point the same way: LDL is >90%, triglycerides are 77th, HbA1c is >90%, and type 2 diabetes is also high. This is the core heart-and-metabolism cluster.

A useful way to explain this: ApoB is not just a lab number people argue about online. The evidence lines up unusually well. The simplest mental model is still the best one: more particles over more years means more chances for particles to enter artery walls.

For this sample, this can point directly to measurement. A measured ApoB result can either confirm the DNA pattern or calm it down. LDL-C matters too, but ApoB is the cleanest way to check whether the particle-count story is actually active now.

At 37, this is a useful prevention window because blood pressure, ApoB/LDL, HbA1c or glucose, waist trend, sleep, food pattern, and activity are still very modifiable.

Triglycerides are less elegant than ApoB but very revealing. They often behave like metabolic engine smoke: not always the main damaging thing by themselves, but a visible sign that insulin resistance, liver fat export, alcohol sensitivity, recent diet, or remnant-particle clearance may be part of the story.

Sample Customer's triglyceride score is around the 77th percentile. That matters because it sits right between the glucose signals and the lipid-particle signals: HbA1c and type 2 diabetes are high, LDL is very high, ApoB is higher, HDL is lower, and nonalcoholic fatty liver disease is also somewhat higher. This makes triglycerides a bridge trait in Sample Customer's report rather than a side note.

A useful misconception to clear up: high triglycerides are often not mainly a "you ate too much fat" story. In common metabolic patterns, refined carbohydrates, fructose, insulin resistance, alcohol, sleep, body composition, and liver fat can be more relevant. The more technical version is remnant biology: triglyceride-rich particles and their remnants can contribute to artery-risk exposure, especially when ApoB is also high.

For this sample, fasting triglycerides are useful because they give feedback. Unlike many DNA findings, this one can move substantially with real life: alcohol pattern, carbohydrate quality, meal timing, training, sleep, weight trend, and medication context all get a vote.

At 37, this is foundation-building rather than decline management: protect training capacity with progressive strength or aerobic work, enough recovery, protein, and injury-aware progression.

HDL cholesterol used to be the easy part of the lipid story: high HDL was "good," low HDL was "bad." The modern version is more interesting. Raising HDL-C with drugs has not reliably reduced cardiovascular events, and lipid experts increasingly care about HDL function, particle behaviour, triglycerides, insulin resistance, and ApoB rather than HDL-C as a heroic standalone number.

Sample Customer's HDL score sits around the 25th percentile, so the inherited tendency is lower than average. That could sound negative, but HDL is more useful as part of the wider metabolic-lipid picture: triglycerides are 77th, ApoB is 78th, LDL is >90th, and HbA1c/type 2 diabetes also lean upward. The better question is not "how do we raise HDL?" but "what does the whole particle-and-metabolic picture look like?"

The practical angle is that low HDL often travels with higher triglycerides and insulin resistance. Exercise, improved insulin sensitivity, less smoking exposure, better body composition, and fewer refined carbs can move HDL, but the win is usually the broader metabolic improvement, not the HDL number itself.

Constipation is not just "not enough fibre." The more interesting version is transit time: how quickly the gut moves contents along, how the migrating motor complex clears the small intestine between meals, how methane-producing microbes can slow transit, and how timing, sleep, stress, hydration, and movement all feed into motility.

Sample Customer's constipation score is in the >90% category, so this is one of the more active gut findings. It fits with the very high IBS signal, but it points in a different direction from diarrhea, which is lower. The useful next step is to make that useful: the genetic picture leans more toward slow-transit or constipation-pattern IBS than toward fast-transit looseness.

A useful plain-English angle here is the transit-time and gut microbes point. Slow transit can change the gut ecosystem because material sits longer, fermentation patterns shift, gas profiles change, and symptoms can get blamed on individual foods when the deeper issue is pace and clearance.

For this sample, if symptoms exist, a stool-form and timing log is more useful than guessing from a percentile alone: Bristol type, frequency, straining, bloating, meal timing, sleep, alcohol, caffeine, hydration, travel, stress, and medication context.

Serum iron is the amount of iron circulating in blood at the time of the test. It is useful, but noisy: it varies by time of day, recent intake, inflammation, hepcidin, illness, blood loss, and iron stores. That is why it can usually be interpreted with ferritin, transferrin saturation, iron-binding capacity, CRP/inflammation context, and a blood count.

Sample Customer's serum iron score is in the <10% category, making it one of the clearer energy/recovery signals. It pairs with high hepcidin context and mildly lower ferritin, while hemoglobin, MCH, MCV, hematocrit, and red blood cell count look favourable. So the story is not "red-cell capacity is genetically poor." It is more specific: iron availability is worth checking properly.

The useful angle is strongest in the athlete/fatigue lane: low ferritin or iron availability can be misread as overtraining, poor motivation, or vague burnout, especially when hemoglobin has not yet fallen. That is a useful report insight because it points toward basic labs rather than exotic explanations.

For this sample, serum iron is practical to check directly. If fatigue is real, the useful next step is not iron supplementation from DNA alone; it is a full iron panel and a reasoned interpretation.

Reaction time sounds simple, but it is really a mix of attention, processing speed, motor response, fatigue, sleep, practice, visual input, stress, and the test itself. The DNA signal is also modest: reaction-time DNA result is built from many tiny genetic nudges and current models explain only a small slice of real-world performance.

Sample Customer's reaction-time score is around the 11th percentile. Here, lower means faster: it points toward shorter reaction time, not poorer performance. This is still curiosity context, not a verdict on intelligence or ability, because sleep, attention, practice, visual input, stress, and the test itself all matter.

A useful nuance: reaction time variability may matter as much as mean speed. Fluctuations in response speed have been studied as an endophenotype for neuropsychiatric conditions, but the genetics are weakly predictive and ancestry portability is limited.

For this sample, the cognition signals are mixed in an interesting way, with memory looking a little better than average and reaction-time genetics pointing faster.

Magnesium is involved in ATP handling, muscle relaxation, nerve signalling, sleep, stress response, and hundreds of enzyme reactions. The tricky part is measurement: serum magnesium is easy to test but can look normal even when intracellular or functional status is not ideal.

Sample Customer's serum magnesium score is around the 15th percentile, so the inherited tendency is lower. That is not a diagnosis, but it is interesting next to the higher fatigue score, distinctive sleep-duration signal, and recovery-related context. It is also one of the more everyday-actionable nutrient findings because measured magnesium status, diet pattern, training load, sweat loss, stress, and symptoms can all be checked.

The useful angle is performance-heavy: discussion around soreness, cortisol, training stress, and magnesium forms. The careful version is: magnesium is not just a generic supplement trope; it is tied to energy chemistry and neuromuscular recovery.

For this sample, this should be a "check and contextualise" note. If cramps, poor sleep, heavy training, high stress, or fatigue are present, magnesium intake/status may be worth reviewing, ideally with sensible lab and clinical context rather than megadosing blindly.

Eosinophilic esophagitis is a good example of allergy biology showing up in a very specific place: the oesophagus. It can look like reflux, but the clues are different: food sticking, swallowing difficulty, food impaction, rings or furrows on endoscopy, and biopsy-confirmed eosinophils.

Sample Customer's EoE score is around the 81st percentile, so this is a higher context. It is especially interesting beside very high allergic rhinitis and higher asthma. But eosinophil count itself is lower, so This does not imply globally high eosinophil biology from DNA alone.

The strongest practical story is the biopsy/diagnosis point. EoE is easy to miss if the endoscopy looks only mildly abnormal or if too few biopsies are taken. The diagnosis depends on symptoms plus adequate sampling, not just a visual impression.

For this sample, the practical route is very specific: dysphagia, food sticking, slow eating, needing liquid to swallow solids, reflux that is not behave like ordinary GERD, food-trigger patterns, and atopy history.

Physical activity genetics is interesting because movement habits, motivation, reward, energy, body composition, and heart-and-metabolism risk all overlap. But it is also easy to misuse: a physical-activity DNA result can sound like it is labelling someone's discipline, which is not helpful.

For this sample, this is lifestyle-proxy context. It is not a personal finding or a statement about motivation. The better movement anchors are VO2max, appendicular lean mass, grip strength, bone density, and actual activity baseline.

A useful gene-environment point: genetic propensity for movement can correlate with lower heart-and-metabolism risk, but environment and structure can override or amplify the tendency.

For this sample, the better plain-language question is practical: what is the current activity baseline, what is measurable, and what experiment should be run next?

Butyrate is one of the more useful gut chemistry clues to explain because it has a clear job: it is made by microbes fermenting fibre, fuels colon cells, supports barrier function, and can signal through routes linked to inflammation and metabolism. Isobutyrate is related, but comes more from protein fermentation.

Sample Customer's butyrate/isobutyrate score is in the >90% category and is treated as a background clue. This is not a disease-risk finding. It is gut-chemistry background. It becomes interesting beside the very high IBS score and lower acetate context, because it hints that the fermentation profile may be distinctive rather than simply "low short-chain fatty acids."

The best plain-English angle is the fibre-to-microbe-to-short-chain fatty acid chain: fibre and resistant starch feed specific bacteria, which produce short-chain fatty acids, which then affect colon cells and gut signalling. The useful point is to keep that way it works without implying a supplement plan from DNA alone.

For this sample, if gut symptoms are present, the practical experiment is not "more butyrate" in the abstract; it is careful response-tracking to fibre type, resistant starch, FODMAP load, fermented foods, and symptom patterns.

Hypothyroidism is one of those traits where the interesting story is not just "low thyroid hormone". A large share of real-world hypothyroidism is Hashimoto's thyroiditis, an autoimmune thyroid condition, so the DNA signal often sits closer to immune regulation than to a simple nutrient-deficiency story.

Sample Customer's score is below the <10% category, which is strongly reassuring. Thyroid disease is not one of the louder inherited signals here. If thyroid symptoms ever mattered in real life, TSH, free T4, free T3, anti-TPO antibodies, anti-thyroglobulin antibodies, medication history, and family history would carry much more weight than DNA alone.

A useful misconception correction: hypothyroidism is not just about iodine. Autoimmunity, thyroid antibodies, pregnancy/postpartum context, infection history, medication effects, and thyroid-gland biology can all matter. Speculative environmental-trigger claims are best left out unless separately verified.

For this sample, the strongest sentence is simple: inherited hypothyroidism tendency looks unusually quiet here.

Taurine is often discussed as a calming amino acid, but the more interesting version is stress-system recovery. It sits near GABA tone, glutamate clearance, cortisol rhythm, and the evening shift from alertness into parasympathetic downshift.

Sample Customer's taurine score is in the >90% category, making it one of the standout sleep-chemistry findings. It does not mean "you need taurine" or as a treatment suggestion. It is background that may help explain why the sleep picture includes stress, alertness, and brain-chemistry balance rather than just hours asleep.

A strong "off switch" framing: taurine sits near the body's move out of emergency mode, especially in wired-but-tired sleep contexts. That makes it interesting beside glutamate and cortisol rhythm, but it can stay as biology colour rather than dose advice.

For this sample, it pairs naturally with high glutamate, high serotonin, lower cortisol context, and anxiety/stress-system findings.

Hepcidin is the master valve of iron handling. When hepcidin is high, it tells the body to close iron-release gates, reducing iron release from gut cells and storage cells into circulation. That is useful during infection, but it can also create the classic puzzle of iron being present in storage while less available for red-cell production.

Sample Customer's hepcidin score is in the >90% category and is treated as a background clue. This is one of the most interesting findings in the iron area because it helps explain why serum iron, ferritin, inflammation, and hemoglobin can disagree. Sample Customer also has serum iron in the <10% category, ferritin around the 40th, and favourable hemoglobin/hematocrit context.

This finding has a useful practical story: plain-English explanations of hepcidin are genuinely useful. Inflammatory signals can push hepcidin up, trapping iron and making ordinary supplementation less straightforward. Conversely, low-hepcidin true deficiency is a different story. That distinction is exactly why a full iron panel is better than one marker.

For this sample, this should be an interpretation note, not a treatment note. If fatigue, low serum iron, restless legs, exercise tolerance, or blood-count changes are relevant, the useful stack is ferritin, transferrin saturation, serum iron, iron-binding capacity, inflammation markers, full blood count, and B12/folate context.

Tinnitus is the perception of ringing, buzzing, or other sound without an external source. It is often linked to noise exposure, hearing loss, hidden cochlear damage, stress load, migraine-like sensory routes, sleep disruption, and central auditory plasticity.

Sample Customer's tinnitus score is in the <10% category, which is strongly reassuring. This is exactly the kind of finding that can belong in Positive & reassuring: it is human, recognisable, and daily-life relevant rather than abstract.

The useful angle is strongest here. Huberman/Stankovic-style discussion framed tinnitus as a mix of genetics, environment, hearing resilience, neural adaptation, and prevention. The interesting part is that tinnitus is not just "old ears" or "one loud concert"; it is a system where exposure and susceptibility interact.

For this sample, this finding can be calming but still sensible. Lower inherited tendency is not permission to ignore loud sound; ear protection and sane volume habits still matter. But the DNA layer does not point toward tinnitus as a likely inherited weak spot.

Vitamin D is partly about sunlight, partly about diet and supplements, and partly about genetics. variants in skin synthesis, binding proteins, activation enzymes, degradation, and receptor biology can all shift measured 25(OH)D.

Sample Customer's vitamin D score is in the >90% category, which is favourable. This is one of the more reassuring energy and immune-background clues, especially next to a higher fatigue score and lower magnesium/iron tendencies.

A useful way to read this is the sunlight-versus-supplement debate, which can get overdramatic online. The plain-language version should be calmer: sun exposure, latitude, skin type, season, body composition, diet, supplements, and genetics all affect measured vitamin D. The blood test still decides whether the favourable tendency is visible.

For this sample, it is not a reason to ignore measurement, but it is a nice counterweight: the DNA layer does not point toward low vitamin D.

Insomnia genetics covers difficulty falling asleep, staying asleep, or waking too early with daytime impairment. It overlaps with arousal systems, stress biology, chronotype, light timing, and mood traits, but the score itself is not a sleep diary.

Sample Customer's insomnia score is in the <10% category, which is strongly reassuring. That is important because other sleep-background clues are more active: chronotype is evening-leaning, daytime sleepiness is mildly higher, and glutamate is higher. It is not useful to make the sleep area sound uniformly problematic.

A useful counterintuitive point: sleep deprivation can push the brain into a hyperexcited, inflammatory molecular state. That is a good reason to take sleep seriously, but for Sample Customer the inherited insomnia tendency itself looks quiet.

For this sample, if sleep issues exist, they may be more about timing, fatigue, airway, stress, or environment than a strong inherited insomnia signal.

Omega-6 percentage is not automatically bad. Linoleic acid and arachidonic-acid routes are part of normal biology. The interesting part is balance: omega-6 and omega-3 families compete for related enzymes and feed different signalling molecules, so the same omega-6 signal means more when EPA is lower.

Sample Customer's score is in the >90% category, which is high enough to be worth noting as context. Because the evidence strength for these nutrient DNA-score findings is weaker, the practical version is "measure and review diet" rather than a hard health claim.

The lively seed-oil debate, including the idea that modern diets push the omega-6:omega-3 ratio much higher than ancestral patterns. The calmer version is less ideological: processed-food oils can raise linoleic-acid exposure, omega-3 can compete with omega-6 routes, and a measured fatty-acid profile is better than guessing.

For this sample, the practical follow-up would be RBC fatty acids or omega-3 index, oily fish/algae intake, processed-food oil exposure, and triglyceride/heart-and-processing context.

Sleep duration genetics is not simply "more sleep is good" or "less sleep is impressive." Rare natural short sleepers exist, but most people do not carry those unusual DNA differences. For most people, duration only makes sense beside sleep quality, timing, daytime function, and recovery need.

Sample Customer's sleep duration score is in the >90% category, so This is notable. It may suggest a longer-sleep tendency or greater sleep-need pattern, especially beside fatigue and mild daytime sleepiness. By itself, it is not a problem.

A good contrast: rare DEC2/ADRB1/SIK3 short-sleep DNA differences show that some people can genuinely thrive on less sleep, but they are exceptions. The ordinary lesson is to match sleep opportunity to function rather than chase a heroic number.

For this sample, the useful question is whether more sleep opportunity improves reaction time, fatigue, mood, training recovery, or daytime dips.

Kynurenine is one of the routes tryptophan can take in the body. Under stress or immune activation, more tryptophan can be pushed down this route instead of staying in the sleep-and-mood chemistry lane.

Sample Customer's kynurenine score is in the <10% category, which is broadly reassuring. It is not a measured blood level, but it does mean this particular stress-tryptophan route is not one of the louder sleep findings.

A good switch metaphor: kynurenine can represent tryptophan being routed toward stress chemistry rather than toward sleep-and-mood chemistry. Sample Customer's result points the other way.

It is a calming counterweight beside the higher anxiety, fatigue, and glutamate results.

Bilirubin is a useful reminder that not every "high" lab value means the same thing. Total bilirubin can rise because of liver or bile-duct disease, red-blood-cell breakdown, medication effects, or a common inherited pattern such as Gilbert's syndrome, where bilirubin processing runs a little slower.

Sample Customer's total bilirubin score is in the >90% category, and it works best as a lab-interpretation clue rather than a disease-risk alarm. If bilirubin ever looks mildly high in bloodwork, do not jump straight to a generic liver-damage story. Check direct vs indirect bilirubin, liver enzymes, red-cell breakdown, fasting, illness, and whether a benign Gilbert-like pattern fits.

A good medical angle: inherited bilirubin conditions are not just names; they map to different steps in bilirubin processing. In plain English: mild isolated bilirubin elevation can be an interpretation issue, not automatically liver damage.

For this sample, this is a note for interpreting future bloodwork. It becomes useful only when paired with real bilirubin fractions and the rest of the liver panel.

C-reactive protein is a liver-made inflammation marker. The high-sensitivity version can pick up quieter inflammation that sits below obvious infection or acute illness, especially in heart-and-metabolism risk discussions.

Sample Customer's CRP score is in the <10% category, which is reassuring. Several immune and allergy results are higher, including lupus and allergic rhinitis, but the inherited baseline CRP tendency looks quiet.

The strongest practical point is the distinction between tendency and current state. CRP is useful because it is easy to measure, but it is not disease-specific. It rises with infection, injury, body weight, autoimmune flares, and plenty of ordinary inflammatory states. A low inherited tendency is calming, but a measured hs-CRP is what tells you what is happening now.

For this sample, this is a low inherited inflammation-set-point clue, not proof that inflammation is absent.

Choline is one of the few nutrient findings that can actually tell an interesting story. The body uses it to build cell membranes, move fat out of the liver, make a nerve signal, and support nutrient recycling. So it sits at the crossroads of liver, brain, and fat handling.

Sample Customer's score is in the <10% category, which makes it the clearest nutrient signal. It is not a deficiency call from DNA, but it is a sensible flag for intake and measurement. The practical question is whether Sample Customer's diet regularly contains choline-rich foods such as eggs, fish, meat, liver, soy, legumes, or whether intake is low.

The strongest practical hook here: only a small minority of US adults are often reported to meet adequate intake, and controlled low-choline feeding studies have produced fatty liver or muscle-damage signals in many men and postmenopausal women. Pregnancy cognition data is less relevant to Sample Customer personally, but it shows why choline is treated as more than a minor micronutrient.

For this sample, the measured version is best: check intake first, consider measured choline/betaine or homocysteine if available, and do not jump straight from DNA to supplementation.

Serotonin is often oversimplified as the happiness chemical, but the real biology is broader. It is involved in mood, sleep architecture, stress reactivity, gut-brain signalling, the brain's ability to adapt, and how the brain updates after experience.

Sample Customer's serotonin score is around the 90th percentile, making it one of the more distinctive sleep-chemistry background clues. It does not mean a measured serotonin level or as a mental-health label. It is better framed as background beside REM/emotion regulation, anxiety, depression, and sleep timing.

The right corrective: low serotonin is not a clean direct cause of depression, yet serotonin-acting treatments can still help through downstream plasticity and circuit effects. That nuance makes the finding more credible than old chemical-imbalance language.

For this sample, it pairs naturally with high anxiety context, higher depression context, high glutamate, and the sleep/circadian findings, but it can stay explanatory rather than diagnostic.

Tryptophan is the starting material for a few different body routes. Some of it feeds serotonin and melatonin biology; some can be diverted toward kynurenine, especially when the immune system is activated. That makes it a useful bridge between sleep, mood, and metabolism.

Sample Customer's tryptophan score is around the 11th percentile. The interesting part is the pattern: serotonin is high, kynurenine is very low, and tryptophan itself is low. This is chemistry colour, not a deficiency statement.

A useful way to explain this is that tryptophan can sit upstream of sleep chemistry without turning into a simple supplement story. It does not mean "more tryptophan equals better sleep."

For this sample, this is a good sleep-chemistry curiosity: distinctive enough to be interesting, but not direct enough to act on alone.

GERD is often explained as "too much acid," but the more useful mental model is acid in the wrong place. Reflux is usually about the barrier between stomach and oesophagus: transient lower-oesophageal-sphincter relaxations, pressure, motility, hiatal hernia, clearance, meal timing, and body position.

Sample Customer's GERD score is around the 13th percentile, which is strongly reassuring. That is useful because the gut area has several louder findings. The inherited reflux tendency itself looks quiet, so it is not useful to make the gut story feel uniformly concerning.

A useful myth-busting angle: Acidic foods are not necessarily the whole story, PPIs work by reducing acid exposure rather than fixing the mechanical reflux event, and eosinophilic oesophagitis can mimic reflux symptoms when dysphagia is present. Those are good explanatory details, but Sample Customer's genetic finding is calm.

For this sample, if reflux symptoms exist, the symptom pattern matters most, especially alarm features like swallowing difficulty, bleeding, weight loss, or persistent symptoms. But DNA-wise, GERD is not the leading gut signal.

Glutamate is the brain's main excitatory neurotransmitter. It is useful during the day for learning, alertness, and signalling, but sleep needs a shift toward quieter, more inhibitory tone. That is why glutamate/GABA balance shows up so often in sleep and "wired but tired" discussions.

Sample Customer's glutamate score is around the 87th percentile, which makes it one of the more distinctive sleep-chemistry clues. It does not mean measured brain glutamate is high, and it is not a diagnosis. It is a clue that wired-brain-chemistry angle may be more relevant than average.

The strongest practical story is the glutamate-to-GABA balance: glutamate drives wakefulness, while GABA supports downshifting. The useful point is to keep that mental model, but avoid turning it into a supplement recipe from DNA alone.

For this sample, it is especially interesting beside anxiety, reaction time, chronotype, and sleepiness context. If symptoms fit, the practical layer is sleep onset, evening stimulation, caffeine, stress, screens, exercise timing, and response to calming routines.

Total cholesterol is a blunt number. It bundles LDL, HDL, VLDL, remnants, and other cholesterol-carrying particles into one total. That makes it familiar, but not always the most revealing lipid measure.

Sample Customer's total cholesterol score is around the 13th percentile, which is low and reassuring. This is one of the more interesting contradictions in the lipid area: total cholesterol genetics look low, while LDL cholesterol is >90th and ApoB is 78th. So the useful point is not "Sample Customer has high cholesterol genetics" in a generic sense. It is more precise: the pattern points more toward LDL/ApoB particle biology and triglyceride-metabolic context than toward a globally high cholesterol tendency.

The strongest practical story is the difference between classic familial hypercholesterolemia and many tiny genetic nudges cholesterol. The surprising stat worth carrying forward is that many people with very high LDL do not have one dramatic FH mutation; they have a stack of smaller many tiny genetic nudges effects. For this sample, though, this total-cholesterol finding itself is not the high signal.

This finding is valuable because it prevents the lipid area from sounding lazy. Total cholesterol is low genetically; LDL/ApoB are the more important findings to understand and measure.

Serum albumin is often misread as a simple protein-intake marker. It is not. Albumin is made by the liver, helps maintain fluid balance, transports hormones and other molecules, and tends to fall with inflammation, some kidney losses, severe illness, poor nutrition, or liver synthetic problems.

Sample Customer's serum albumin score is around the 86th percentile, which is favourable context. This is useful because the liver/kidney area has some mixed findings: SERPINA1 marker detected, NAFLD/MASLD somewhat higher, chronic liver disease/advanced liver scarring higher, and albuminuria higher. Favourable albumin genetics help keep the picture balanced.

The strongest useful point was a misconception: albumin and total protein do not prove someone ate enough protein yesterday or built more muscle. They are pattern markers, and when abnormal they need inflammation, kidney, liver, hydration, and protein-fraction context.

For this sample, it does not erase liver or kidney follow-up findings, but it is one of the better calming signals in that area.

Chronic pain genetics is messy because pain has many doors into the same room: injury, nerves, inflammation, migraine biology, sleep disruption, mood, biomechanics, and central sensitisation. A broad DNA result is never the whole story.

Sample Customer's chronic pain score is around the 15th percentile, which is reassuring. This is a helpful counterweight because migraine and osteoporosis are higher. The DNA layer does not point toward broad chronic-pain vulnerability as a leading movement/pain story.

This is reassuring without pretending pain is simple. Sample Customer's broad chronic-pain tendency is low, while migraine is higher and osteoporosis needs attention. Broad pain vulnerability is not the loud signal, but specific pain patterns still deserve to be read on their own terms.

For this sample, if pain exists, it can still be assessed by pattern and function, but the inherited chronic-pain tendency itself is low.

Neutrophils are the fast-response white blood cells. They move quickly during infection, injury, inflammation, stress, steroid exposure, smoking, and other real-world triggers, so a single measured count is usually more about current context than inherited baseline.

Sample Customer's neutrophil count score is around the 85th percentile, which this report treats as favourable context. It does not mean "better immunity" in a simple way, and it does not diagnose inflammation. It just suggests the inherited baseline is not low.

The careful read is that there is not yet a strong plain-English story for neutrophil DNA result, but the interesting genetics point is ancestry and baseline. Some population-specific DNA differences can shift normal neutrophil ranges, so the right interpretation of blood counts sometimes depends on ancestry-aware reference context.

For this sample, this is quiet background. It may help round out the energy/recovery picture, but fatigue, iron handling, glucose, sleep, and training load are more useful levers than neutrophil genetics.

Vitamin B12 sits at the intersection of nerve health, red-cell production, nutrient recycling, energy, and gut absorption. It is also a good example of why serum levels can be misleading: supplementation, binding proteins, absorption defects, and functional markers can disagree.

Sample Customer's vitamin B12 score is around the 85th percentile, which is favourable context. That helps balance the higher fatigue score and the detected FUT2 B12-background marker. This does not imply a B12 problem from FUT2 when the broader B12 tendency itself looks strong.

A useful caution: serum B12 can look high while functional deficiency exists in rare absorption or transport contexts, so symptoms and functional B12 markers such as functional B12 markers such as MMA or homocysteine can matter. For this sample, though, the default interpretation is positive unless real symptoms or measured markers suggest otherwise.

For this sample, B12 is positive context with a small caveat: if fatigue, neuropathy symptoms, gut history, metformin/PPI use, or unusual blood count patterns are present, use functional markers rather than serum B12 alone.

Eosinophils are immune cells that often show up in allergic and type 2 inflammation: asthma, allergic disease, drug reactions, parasites, some allergy-like gut conditions, and some inflammatory patterns. The count is not the whole story, but it is a useful clue when symptoms point that way.

Sample Customer's eosinophil-count score is around the 17th percentile, which is relatively low context. That is useful because allergic rhinitis is very high, asthma is higher, and the allergy-like swallowing/reflux condition is higher. The useful read is the atopy susceptibility is real, but the inherited eosinophil-count tendency itself is not high.

A useful practical framing: eosinophils are not a static identity marker. They can move with allergens, infections, medications, airway inflammation, and time. In asthma, higher blood eosinophils can help identify a more allergy-leaning pattern and guide treatment choices.

For this sample, if airway, skin, or swallowing symptoms exist, measured blood count, allergy testing, breathing tests, and symptom pattern matter more than this DNA result finding.

SHBG is one of the more useful "wait, what does that actually mean?" hormone traits. It is made mainly by the liver and binds sex hormones, especially testosterone and estradiol. That means total hormone levels can look one way while free, biologically available hormone tells a different story.

Sample Customer's SHBG score is around the 82nd percentile. This is not automatically good or bad. It is context: higher SHBG can make total testosterone less self-explanatory, because more hormone may be bound rather than freely available.

A strong liver-and-metabolism angle. SHBG is often discussed in PCOS, insulin resistance, fatty liver, advanced liver scarring, and gynecomastia because the liver is not just clearing hormones; it is helping decide how much hormone is available to tissues.

For this sample, this should be paired with total testosterone rather than interpreted alone. If hormones were ever a real question, the practical panel would be morning total testosterone, calculated or measured free testosterone, SHBG and pituitary hormones, prolactin, estradiol, thyroid markers, liver markers, sleep, medications, and symptoms.

Appendicular lean mass is muscle mass in the arms and legs. It matters because limb muscle is tied to training capacity, glucose disposal, functional independence, joint protection, bone loading, and resilience with ageing.

Sample Customer's appendicular lean mass score is around the 81st percentile, which is a genuinely positive movement finding. It can be one of the reassuring findings: the DNA layer points toward useful body-composition assets, even though VO2max genetics are lower.

A useful angle is a great distinction: strength and power can decline faster than muscle mass. That means lean mass is an asset, but it is not the whole story. Functional tests like grip strength, sit-to-stand, gait speed, and power output matter.

For this sample, it also links nicely to the later aerobic-capacity story: build the engine without ignoring the strength base.

Mean corpuscular hemoglobin, or MCH, is basically how much oxygen-carrying hemoglobin sits inside each red blood cell. It sounds boring until fatigue enters the picture, because then the question becomes: is oxygen delivery part of the story, or should attention move elsewhere?

Sample Customer's MCH score is around the 81st percentile, which is favourable. It sits alongside higher hemoglobin, higher red blood cell count, and near-typical-to-favourable red-cell size. That helps balance the low serum iron finding: the inherited picture does not suggest weak red-cell hemoglobin overall.

The useful point is that one blood-count number is never the whole story. Red-cell size, hemoglobin, ferritin, transferrin saturation, B12, folate, and inflammation markers all change the meaning.

For this sample, this is reassuring energy context. If fatigue is present, real blood-count values can help decide whether oxygen delivery is part of the picture or whether attention should move to sleep, glucose, thyroid, training load, inflammation, or iron availability.

Osteoarthritis is not simply wear and tear. It is a whole-joint process involving cartilage, bone, ligaments, muscle, synovium, inflammation, past injury, load, alignment, and metabolic context.

Sample Customer's osteoarthritis score is around the 20th percentile, which is reassuring. That is useful because the movement area contains higher osteoporosis, migraine, and gout signals. Joint-degeneration genetics are not one of the louder inherited stories.

The best practical point: rest is not automatically protective. Cartilage and joints often need the right kind of loading, while symptoms, injury history, weight, inflammation, and strength determine what the joint can tolerate.

For this sample, if joint symptoms exist, they should be understood by joint, pattern, imaging, and function, but the inherited OA tendency itself is lower.

Phenylalanine is an essential amino acid and an upstream building block for tyrosine, which then feeds into dopamine and adrenaline-family chemistry. That makes it more of an alertness, motivation, reward, and stress-response finding than a direct sleep-disorder finding.

Sample Customer's phenylalanine score is around the 80th percentile, so it is one of the more noticeable amino-acid clues. It is background, especially beside higher glutamate and faster reaction time, not a supplement or diet instruction.

The useful angle is traffic flow rather than deficiency. Phenylalanine sits upstream of tyrosine, and tyrosine sits upstream of daytime-drive chemistry. That is interesting beside Sample Customer's higher glutamate and lower reaction-time score, but it is not a primary insomnia signal and it is not a supplement instruction.

For this sample, it is part of the broader sleep/neurochemistry picture, not a standalone action item.

Resting heart rate is one of those numbers people tend to moralise, but the biology is more interesting than that. Training, sleep, illness, caffeine, stress, thyroid status, medications, and hydration all move it around. Underneath that, though, there is also a partly inherited set point.

Sample Customer's resting heart rate score is around the 21st percentile, which points toward a lower inherited tendency. That is generally a reassuring cardiovascular background clue, especially paired with the higher heart-rate variability signal here. It does not mean "athlete" by itself, and it does not make a single wearable number meaningful, but it does make a lower resting baseline feel more biologically plausible if seen in real data.

A useful plain-English angle here is the athlete bradycardia angle. In one elite endurance-athlete discussion, very low minimum heart rates were common and often benign, and the athletes were enriched for low heart-rate DNA result. That is the useful mental model: training can amplify the real-world result, but some people seem genetically pre-loaded for a lower cardiac set point.

For this sample, the practical thing is not to chase the lowest possible number; it is to compare the DNA tendency with actual resting heart rate, HRV, symptoms, sleep, and training load.

Cystatin C is one of the more useful kidney markers because it is less tied to muscle mass than creatinine. Creatinine can look high in muscular people and deceptively normal in people with low muscle mass; cystatin C gives a different view of filtration.

Sample Customer's cystatin C score is around the 22nd percentile, which is reassuring here. It helps balance the kidney story, because albuminuria is much higher and chronic kidney disease is somewhat higher. In other words, the inherited filtration-marker context is not uniformly concerning.

A useful measurement angle: cystatin C can catch kidney-function signals that creatinine misses, and newer ancestry-diverse large studies are finding kidney-function DNA regions that older European-heavy studies could miss. That matters because kidney risk can be misread when the tool itself is biased or confounded.

For this sample, this is a calming but useful note. If kidney follow-up happens, measured cystatin C can sit alongside creatinine-based eGFR and urine albumin-to-creatinine ratio, giving a more complete picture than creatinine alone.

Hemoglobin is the oxygen-carrying protein inside red blood cells. It is where iron, B12, folate, the hormone that tells the body to make red blood cells, inflammation, red-cell production, and blood loss all eventually show up in a in practice familiar number.

Sample Customer's hemoglobin score is around the 78th percentile, which is favourable context. This is important because serum iron is lower and ferritin tendency is mildly lower. The DNA layer is not saying the whole red-cell system is weak; it is saying iron handling is worth checking, while hemoglobin tendency itself looks stronger.

The biology is intuitive enough: hemoglobin is where the iron-and-red-cell system shows up in a number people recognise. Hepcidin affects how available iron is; ferritin reflects storage and inflammation; B12 and folate affect red-cell production; and hemoglobin is the output people usually notice when it drops.

For this sample, if fatigue exists, measured hemoglobin can help distinguish oxygen-carrying issues from sleep, glucose, training load, mood, thyroid, or post-viral causes.

Polyunsaturated fatty acids include omega-3 and omega-6 families, so the total number can be less useful than the pattern inside it. A lower total PUFA tendency can mean different things depending on whether EPA, DHA, linoleic acid, arachidonic acid, and oxidation context are high or low.

Sample Customer's score is around the 23rd percentile. On its own, that is not a problem or a benefit. The better story is the contrast inside the fatty-acid picture: omega-6 percentage is high, EPA is lower, DHA is mildly favourable, and broad omega-3 is slightly lower. That points toward fatty-acid balance rather than total PUFA as the main concept.

The noisier version of this topic often focuses on PUFA oxidation: these fats are chemically more fragile, which is why food quality, cooking, storage, supplement oxidation, antioxidant context, and lipid peroxidation can matter. But "PUFA is bad" is too crude. PUFAs are essential; excess, imbalance, and oxidation are the more interesting questions.

For this sample, if this ever becomes actionable, the right measurement is a full RBC or plasma fatty-acid panel, not the total DNA alone.

Alcohol consumption genetics is interesting because it sits between metabolism and behaviour. Some DNA differences change how alcohol feels in the body, while broader many tiny genetic nudges signals overlap with reward sensitivity, stress, impulsivity, and social environment.

For this sample, this is lifestyle-timing context. It is not a way to infer current drinking, self-control, personality, or health behaviour. Current pattern is the result that matters.

A useful framing point: alcohol-use traits are heritable but not deterministic. Family history and genetics can shift susceptibility, but alcohol exposure, culture, stress, sleep, social context, and deliberate choices shape the real outcome.

For this sample, if alcohol is relevant, the better prompt is practical: weekly units, binge pattern, cravings, sleep quality, mood, liver enzymes, triglycerides, medication interactions, and whether support would be useful.

BCO1 is the cleanest version of the "carrots are not retinol" story. The enzyme helps convert beta-carotene from plant foods into active vitamin A. Some people convert less efficiently, which can make preformed retinol from animal foods more dependable than relying only on carotenoids.

For this sample, this context is not active, so there is no detected poor-converter marker claim. It can still explain the general vitamin A concept, but it is not a personal signal.

A strong plain-English hook: plant beta-carotene and active retinol are not interchangeable for everyone. For this sample, the narrower point is that retinol itself is mildly favourable, and this named BCO1 DNA difference evidence is not active.

For this sample, this is a guard against overclaiming, not a new finding.

PEMT is the gene-story version of choline biology. It helps make a choline-based membrane fat internally, which matters for membranes, nutrient recycling, liver fat export, and high-demand states. It is especially interesting because choline need can be shaped by diet, nutrient-recycling context, liver biology, and sex-hormone state.

For this sample, the PEMT background marker is absent or not weighted for Sample Customer. That is important because Sample Customer's broader choline score is low, in the <10% category, but This does not claim a detected PEMT DNA difference as the reason.

A strong pregnancy and maternal-demand angle exists in the wider science, but the useful general lesson here is narrower: choline need is not just about an average intake target; synthesis, diet, and nutrient-recycling context can change the practical picture.

For this sample, this sits behind the choline finding rather than standing alone.

FADS1 and FADS2 are the enzyme-gatekeeper story behind omega-3 and omega-6 conversion. They help explain why plant precursors, marine EPA/DHA, seed-oil exposure, and measured omega-3 index can mean different things in different people.

For this sample, the named FADS background marker is absent or not weighted for Sample Customer. This does not claim a detected FADS conversion DNA result. That matters because Sample Customer does have an interesting fatty-acid pattern elsewhere: omega-6 is high, EPA is lower, DHA is mildly favourable, and broad omega-3 is slightly lower.

The most useful story is the PUFA debate, but the practical version is simple: if fatty-acid status matters, measure it. A full RBC or plasma fatty-acid panel is cleaner than inferring conversion from an inactive DNA difference finding.

For this sample, this sits behind the omega-3, omega-6, EPA, DHA, and PUFA findings rather than standing alone.

GGT is a liver enzyme that often rises with alcohol exposure, fatty liver, bile-duct stress, medications, smoking, oxidative stress, or broader metabolic strain. It is not specific, but it is often useful because it reacts to real-world exposures.

Sample Customer's GGT score is around the 24th percentile, which is reassuring. It sits alongside favourable serum albumin and near-typical ALT as a calmer part of the liver panel. That matters because other liver findings are more active: SERPINA1 marker detected, chronic liver disease/advanced liver scarring higher, NAFLD higher, and AST/ALP mildly higher.

A useful way to frame GGT as a gene-environment readout: not just a static liver marker, but a place where alcohol, liver fat, oxidative stress, and inherited susceptibility can interact. That is interesting, but for Sample Customer the result itself is lower rather than higher.

For this sample, GGT is reassuring liver context. If a real liver panel shows GGT low or normal, that would help calm the liver story; if it is high, it would be more informative because the inherited tendency points the other way.

ADORA2A is the receptor-side caffeine story. CYP1A2 asks how long caffeine hangs around; ADORA2A asks how strongly caffeine's adenosine-blocking effect may land in the brain.

For this sample, this is lifestyle-timing context. It is not being reported as caffeine sensitivity. If caffeine does not disturb sleep, anxiety, or palpitations in real life, this can stay quiet.

The useful split: metabolism speed and receptor sensitivity are different. Someone can clear caffeine normally but still feel wired or anxious, while someone else can clear it slowly but tolerate it subjectively.

For this sample, this is supporting context next to the CYP1A2 caffeine finding. The useful question is what happens after caffeine, not claiming sensitivity from this marker.

HLA-B27 is one of the most famous rheumatology markers because it is strongly associated with ankylosing spondylitis and axial spondyloarthritis. The trap is that fame can make it feel diagnostic when it is not. Many HLA-B27-positive people never develop disease, and some true spondyloarthritis cases are HLA-B27 negative.

For this sample, HLA-B27 is absent or absent or not weighted here. That is separate from the higher ankylosing spondylitis DNA result. The AS result is still worth reading through symptoms, but it does not imply Sample Customer has this famous HLA marker.

A useful plain-English angle is anchoring bias. People can over-focus on HLA-B27 and miss the actual pattern of symptoms. The useful lesson is pattern first: inflammatory back pain, morning stiffness, night pain, improvement with movement, eye inflammation, psoriasis, gut symptoms, family history, and imaging when in practice relevant.

For this sample, the credibility point is simple: HLA markers can be powerful, and absent markers are just as important to leave quiet.

HLA-DQ2 and HLA-DQ8 are central to celiac disease because they help present gluten peptides to T cells. The surprising part is the gap between being genetically permissive and actually having celiac disease: a large share of the population carries permissive HLA, while only a much smaller fraction develops disease.

For this sample, this HLA-DQ2/DQ8 context is absent or not weighted for Sample Customer. That pairs well with the celiac disease DNA result being around the 45th percentile. The combined read is calming: there is no active HLA celiac-susceptibility marker driving the gut story.

A useful angle is immunology detail: celiac-associated HLA may not only present gluten after exposure, but may also help shape a naive T-cell repertoire that is more ready to recognise gluten. That is excellent science colour, but Sample Customer's actual result is the anchor.

For this sample, this does not dismiss symptoms if they exist, especially iron deficiency, persistent GI symptoms, family history, or nutrient issues. But DNA-wise, celiac is not the main gut signal here.

Anticonvulsant medication-response genetics has two different kinds of risk layered together. HLA markers can affect rare immune reactions such as severe blistering or delayed drug-rash reactions, while CYP2C9 can affect phenytoin levels because phenytoin has a narrow safety margin.

For this sample, this does not create a standalone medicine warning. It becomes relevant only if a real prescribing decision is in scope and formal testing is available.

A useful framing: the same drug class can involve both immune-reaction risk and drug-level risk. That is more interesting and more honest than a simple "safe or unsafe" label.

For this sample, if carbamazepine, phenytoin, lamotrigine, or related medicines are ever considered, formal HLA/CYP testing, ancestry context, current medicines, dose, serum levels where relevant, and medical review would guide the plan.

HFE is one of the more vivid genetics stories in the iron world: the "Celtic Curse" pattern where C282Y can drive hereditary hemochromatosis in people with the right DNA difference combination. It is also unusually actionable because confirmed iron overload is measurable and often managed with phlebotomy.

Sample Customer's tracked HFE C282Y/H63D marker was not detected. That is reassuring. It means the iron story does not look like inherited iron overload. The more relevant Sample Customer pattern is low serum iron, mildly lower ferritin, high-context hepcidin, and favourable red-cell oxygen-carrying markers.

Some useful geography and evolutionary colour: high HFE risk hotspots in Ireland and Scotland, a possible historic advantage in iron-poor settings, and a modern mismatch with iron-fortified environments. For this sample, the useful point is simple: the common tracked HFE overload marker is not active.

If iron labs ever look high, measured ferritin and transferrin saturation still decide; the DNA marker alone is not the whole iron system.

Lactase persistence is a classic human-evolution story. Most mammals, including most humans historically, turn lactase down after childhood. Some populations evolved regulatory variants that keep lactase switched on into adulthood, especially in dairy-herding cultures.

For this sample, the tracked European lactase-persistence marker is absent or not weighted for Sample Customer. This is not a health risk, but it is a very understandable everyday trait: milk sugar may be less effortless to digest in adulthood than it is for someone with the persistence marker.

The best plain-English angle is the convergent-evolution angle. Lactase persistence did not arise once. Different dairy-herding populations evolved different solutions, while the European LCT/MCM6 marker became common through strong recent selection and population history.

For this sample, it can be framed practically and lightly: lactose-free dairy, lower-lactose fermented dairy, portion size, lactase tablets, or symptom tracking may matter if dairy causes symptoms. It is not a diagnosis of lactose intolerance because gut injury, gut microbes context, and individual tolerance can change the real-world result.

TMPRSS6 is one of the most interesting iron genes because it helps put the brakes on hepcidin. If TMPRSS6 function is reduced, hepcidin can stay higher, iron absorption can fall, and severe rare forms can cause iron-refractory iron deficiency.

For this sample, the tracked TMPRSS6 context is absent or not weighted for Sample Customer. That means it is not the explanation for the low serum iron signal. The better personalised story is: serum iron is low, hepcidin is high-context, ferritin is mildly lower, transferrin saturation is near typical, and red-cell oxygen markers look favourable.

This finding is useful because it explains why oral iron does not always behave as expected in high-hepcidin states. But this absent/not-weighted marker is background, not an action item.

The useful measurement stack is full iron panel plus blood count, not a TMPRSS6 narrative.

SLCO1B1 is one of the more practical cardiology medication-response genetics stories. The transporter helps move statins into the liver. Reduced transporter function can raise circulating statin exposure and, for some statins and doses, increase muscle-symptom risk.

For this sample, this is medicine-specific context. It is not a general muscle trait or a reason to avoid lipid treatment.

A useful clinical nuance: statin-associated muscle symptoms are real, but attribution can be complicated by nocebo effects, dose, drug interactions, exercise, thyroid status, vitamin D, kidney function, and the specific statin. DNA result is one useful clue, not the whole story.

For this sample, if statin therapy is being considered or muscle symptoms occur, use DNA result, statin type and dose, LDL/ApoB risk, CK if indicated, thyroid/kidney context, interacting medicines, and medical review.

Opioid medication-response genetics is most useful when it prevents the false assumption that every opioid is equivalent. Codeine and tramadol depend heavily on CYP2D6 activation, while receptor and pain-modulation genes such as OPRM1 and COMT may add smaller, more context-dependent effects.

For this sample, this is medicine-specific context. It is not a pain-sensitivity label, an opioid-risk label, or a general health finding.

The most useful plain-English hook: codeine is a medicine the body has to switch on with variable conversion. Poor CYP2D6 processors may get little benefit; very fast processors may get too much active chemistry clue. That makes DNA result in practice relevant for certain drugs, especially in higher-risk settings.

For this sample, if codeine, tramadol, or related opioid questions arise, use formal medication-response genetics guidance, pain indication, previous response, side effects, sedation/respiratory risk, current medicines, and medical review.

CYP2C9 is a workhorse medication-metabolism gene. It is especially important for phenytoin because phenytoin has nonlinear kinetics and a narrow therapeutic window: small exposure differences can become practical toxicity differences.

For this sample, this is medicine-specific context. It is relevant only if a matching medicine is actually relevant.

A useful split: the evidence is strongest and most actionable for phenytoin dosing and monitoring, while NSAID medication-response genetics is more conditional and drug-specific. That distinction matters.

For this sample, if phenytoin or a CYP2C9-relevant painkiller is considered, use DNA result, dose, indication, liver/kidney context, blood-level monitoring where appropriate, side-effect history, and medical review.

ACTN3 is the famous "speed gene" marker because functional alpha-actinin-3 is found in fast-twitch muscle fibres and is enriched in some sprint and power-athlete groups. It is a clear, memorable sports-genetics story, which is exactly why it needs restraint.

For this sample, this ACTN3 context is absent or not weighted for Sample Customer. There is no detected sprint/power DNA result claim here. The more relevant movement signals are the scored traits: lean mass, grip, VO2max, bone density, and injury context.

The most useful story is anecdotes and way it works, but also rightly noted that elite performance is wildly many tiny genetic nudges and training-dependent. A single marker should never be made to carry an identity label.

SLC2A9 and ABCG2 are two of the big urate-handling genes. They help explain why gout genetics is often more about kidney and transporter handling than about dietary purine arithmetic.

For this sample, this context is not active. Urate handling can still be mentioned in the broader gout note, but there is no active SLC2A9 or ABCG2 finding here.

A useful clinical nuance: asymptomatic hyperuricemia is not the same as gout, and treatment decisions depend on flares, crystals, tophi, kidney stones, CKD context, and measured urate rather than genetics alone.

For this sample, the active result is gout at 73rd with serum urate near typical, not a detected urate-transporter DNA difference.

B12 absorption is genuinely interesting. Intrinsic factor, cubilin in the ileum, passive diffusion at high doses, transcobalamin delivery, haptocorrin binding, gut history, metformin, PPIs, and gut microbes context can all make serum B12 harder to interpret than people expect.

For this sample, the tracked PNPLA3 liver context is absent or not weighted for Sample Customer, so it is not a deficiency explanation. The more relevant findings are favourable vitamin B12 genetics and the separate FUT2 B12-background marker, which is conditional rather than diagnostic.

A useful plain-English angle here is that serum B12 can sometimes mislead. Total serum B12 can look fine while active B12 delivery or functional markers are not fine in some contexts. That is worth preserving as an educational note, but not as a personal concern from this marker.

If fatigue, neuropathy symptoms, gut history, metformin/PPI use, or unusual blood count patterns exist, use B12 plus functional B12 markers such as MMA or homocysteine where appropriate. Otherwise, this is background biology.

Red blood cell count is one of the simplest ways the body supports oxygen delivery. It sits in a system with hemoglobin, hematocrit, MCV, MCH, iron availability, B12/folate, inflammation, training load, altitude, hydration, and recovery.

Sample Customer's red blood cell count score is around the 75th percentile, which is favourable context. That matters because fatigue is higher and serum iron is low. The reassuring part is that the red-cell production and oxygen-carrying side of the DNA picture does not look low: hemoglobin, MCH, and red blood cell count all point in a stronger direction.

The useful angle is the performance one: blood markers can explain fatigue and recovery issues that people sometimes mislabel as weak willpower, poor training, or vague burnout. That is a much better story than treating red-cell markers as abstract lab trivia.

For this sample, this is a positive context. If fatigue is present, real blood count markers can show whether oxygen delivery is actually involved; the DNA layer makes low red-cell count less likely as the inherited story.

Heart-rate variability is one of the few traits that connects genetics, physiology, and daily feedback in a way people can actually feel. It measures beat-to-beat variation, and much of that variation reflects the tug-of-war between sympathetic drive and parasympathetic/vagal tone.

Sample Customer's HRV tendency is around the 74th percentile, which is a favourable background clue. It suggests the inherited baseline may be more supportive for recovery and automatic nervous-system flexibility than average. That fits nicely with other more positive physical-background clues here, like lean mass and grip strength.

The interesting part is that HRV is not simply "higher is always better." It is noisy, context-dependent, and sometimes misleading; atrial fibrillation or measurement artefact can produce odd readings. But as a trend, HRV can be a useful dashboard for sleep debt, alcohol, illness, training load, stress, and recovery. Some heritability estimates range widely, roughly 25-70% depending on the metric, but day-to-day behaviour still moves the number a lot.

The practical frame is: use HRV as feedback, not identity. If measured HRV tracks well with sleep, training, alcohol, or stress, it can help tune the routine. If it does not, the trend may be less useful than resting heart rate, subjective recovery, and performance.

Gout is often caricatured as a rich-food disease, but the better story is uric-acid handling. Kidney transporters, genetics, beer, fructose, diuretics, weight, insulin resistance, and urate-lowering therapy often matter more than a simple red-meat morality tale.

Sample Customer's gout score is around the 73rd percentile, so this is a moderately higher movement/pain finding. It is not as loud as migraine or osteoporosis, but it is a real context.

A strong evolutionary angle: humans lost functional uricase, leaving us with higher uric acid than many mammals. That may have carried trade-offs, but in modern life it makes urate handling a more interesting risk route than "too many purines."

For this sample, the practical route is measured serum urate, kidney context, beer/fructose intake, diuretics, metabolic health, and flare history.

White blood cell count is a moving target. Infection, stress, exercise, sleep debt, steroids, smoking, inflammation, and timing can all shift it quickly. Genetics mostly sets a baseline tendency and subtype patterns.

Sample Customer's WBC score is around the 73rd percentile, which works as favourable context. Neutrophil count is also higher/favourable. This helps keep the energy area from reading as globally depleted, even though fatigue, serum iron, and magnesium are more active check findings.

This can stay modest on WBC DNA result, but the useful point is ancestry-aware interpretation. Some people have genetically lower neutrophil counts that are normal for them, while others run higher baselines. Context and trends matter more than one isolated value.

For this sample, this is quiet background. If measured WBC is normal, the finding is mostly reassurance. If measured WBC is high or low, current illness, inflammation, stress, medication, and differential count matter more than the DNA result.

Bone density is one of the rare longevity-adjacent traits that is both genetic and measurable. It responds to loading, hormones, nutrition, vitamin D, medications, age, and fall risk. It can be read alongside osteoporosis risk, not as a separate universe.

Sample Customer's bone density score is around the 72nd percentile, and higher is favourable here. That is reassuring because osteoporosis DNA result is higher elsewhere. The combined message is nuanced: bone-density genetics look like an asset, but osteoporosis/fracture-context still deserves attention.

A strong bone-muscle framing: bone responds to mechanical load, and muscle and bone are part of one adaptive system. That fits Sample Customer's report because appendicular lean mass is also favourable.

For this sample, it can support a confident message: there are bone and muscle assets to build on, while still being sensible about DEXA eligibility and fracture context.

Diarrhea sits at the other end of the transit spectrum from constipation. The interesting version is not just "loose stools"; it is fast movement, less absorption time, more bile acids reaching the colon, possible H2S-producing microbial patterns, and overlap with IBS-D, infection, inflammation, malabsorption, or medication effects.

Sample Customer's diarrhea score is around the 28th percentile, which is relatively reassuring. In context, that is useful because constipation is high and IBS is very high. The useful read is something more specific than "gut sensitivity": the DNA layer leans away from a fast-transit diarrhea pattern and toward constipation/motility patterning.

A good gut microbes-gas angle: some IBS research separates methane-linked constipation patterns from H2S-linked diarrhea patterns. That does not mean a DNA result can subtype gut microbes, but it is a helpful mental model for why two people can both have "IBS" while living in very different gut mechanics.

For this sample, this is reassuring context. It cannot erase symptoms if they exist, especially red flags like blood, nocturnal symptoms, weight change, dehydration, infection exposure, or persistent urgency. But the inherited diarrhea tendency itself is not the loud gut finding.

EPA is the omega-3 finding that points more toward inflammation signalling and resolution. It competes with omega-6 routes and feeds specialised pro-resolving mediators, which is why EPA discussions often end up around vascular inflammation, chronic inflammation, mood, and metabolic health.

Sample Customer's score is around the 29th percentile, which is lower but not extreme. This does not mean low omega-3 status from genetics alone. It is a useful prompt to ask about oily fish intake, supplement use, omega-6-heavy processed foods, and measured omega-3 index if this is in practice or personally relevant.

One compelling angle: EPA is not simply anti-inflammatory in a blunt sense; it helps move the system toward resolution. It also competes with omega-6-derived signalling, so dietary pattern can change the meaning of the same inherited tendency.

For this sample, the practical point is simple: if omega-3 status matters, measure RBC EPA+DHA and review intake before making conclusions.

Homocysteine is a useful blood marker because it turns a vague nutrient story into something checkable. It sits where folate, B12, B6, riboflavin, choline, betaine, kidney function, thyroid status, and blood-vessel health meet. When it is high, it can suggest the recycling system is under strain.

Sample Customer's score is around the 71st percentile. That is not extreme, and it is not a diagnosis, but it is more concrete than many nutrient clues because it can be checked with a fasting homocysteine test.

A useful mental model: homocysteine is a traffic-light marker for nutrient recycling. A high measured value can tell you something is worth checking, even though it does not prove that one specific supplement plan changes long-term outcomes.

For this sample, the practical version is straightforward: if this matters, measure fasting homocysteine and read it with B12, folate, functional B12 markers, B6/B2 where available, kidney function, thyroid status, diet, and choline/betaine intake.

Serum total protein is albumin plus globulins. It is often misused online as if it proves diet quality, muscle mass, or who eats more protein. It does not. It is a composite marker shaped by hydration, inflammation, immune proteins, liver production, kidney losses, and albumin/globulin balance.

Sample Customer's total protein score is around the 71st percentile and is treated as a background clue. Because serum albumin is favourable, this is not a worrying pattern in the DNA layer. It is more of a reminder that protein labs should be split into their components before anyone makes a story out of them.

The useful angle is useful mostly because it pushed back against a common misconception: total protein is not a nutrition scoreboard. If total protein is abnormal in real bloodwork, the question is albumin vs globulin, hydration, inflammation, kidney loss, liver synthetic function, and sometimes electrophoresis.

For this sample, this is a small context. Albumin is the more useful positive signal; total protein just adds interpretation context.

Snoring happens when airflow partially obstructs and soft tissues vibrate. It can be harmless, but it can also point toward airway vulnerability, especially when paired with gasping, witnessed pauses, oxygen dips, or daytime sleepiness.

Sample Customer's snoring score is around the 29th percentile, which is reassuring. It helps balance the sleep-apnea finding: apnea is mildly higher, but the inherited snoring tendency is lower, and BMI and blood-pressure findings are also not high.

The strongest practical story is way it works and red flags: back sleeping, alcohol, sedatives, nasal congestion, allergies, and soft-tissue anatomy can all matter. Snoring is useful less as a genetic identity and more as a symptom clue.

For this sample, if snoring exists in real life, symptom pattern and measurement win over DNA: partner reports, audio apps, oxygen dips, morning headaches, and home sleep testing if red flags are present.

Tyrosine is the catecholamine-precursor finding. It feeds into dopamine, norepinephrine, and epinephrine, so its most intuitive links are alertness, motivation, stress response, and cognitive performance under load.

Sample Customer's tyrosine score is around the 29th percentile, which is lower context. It is not one of the louder sleep-chemistry findings. It is most useful because it contrasts with higher taurine, higher glutamate, higher serotonin, and higher phenylalanine nearby.

The useful angle is timing and balance. Tyrosine belongs more to daytime drive than evening wind-down: attention, motivation, stress response, and performance under pressure. That makes it more interesting next to phenylalanine and reaction time than as a sleep-risk finding.

For this sample, it is not a supplement or performance recommendation.

Acetate is a short-chain fatty acid made largely by gut microbes fermenting fibre. It is the most abundant short-chain fatty acid and sits inside a wider network with butyrate, propionate, fibre type, gut-microbe mix, gut barrier, appetite signalling, and metabolic context.

Sample Customer's acetate score is around the 30th percentile, a lower gut-fermentation clue. This is interesting next to the strong IBS signal because acetate and other short-chain fats are part of the gut fermentation environment. The caveat is simple: a DNA result for acetate is not the same thing as a stool chemistry profile.

The useful idea is personal fermentation: the same fibre can produce different gas, acetate, butyrate, and symptom patterns in different gut microbess. That makes this finding interesting, but still much lighter than the IBS and constipation findings.

For this sample, if gut symptoms are present, response to fibre types, resistant starch, FODMAP load, fermented foods, and gut microbes-disrupting exposures would be more practical than the DNA finding alone.

NAFLD is increasingly being reframed as MASLD: metabolic dysfunction-associated steatotic liver disease. That name is clunky, but the idea is better. It shifts attention away from simply saying "not alcohol" and toward the real drivers: insulin resistance, liver fat handling, triglyceride biology, body composition, blood pressure, glucose, and genetics.

Sample Customer's NAFLD/MASLD score is around the 70th percentile. That is not extreme, but it is directionally important because it sits beside high HbA1c, high type 2 diabetes tendency, higher triglycerides, higher ApoB, and a higher chronic liver disease/advanced liver scarring score. At the same time, liver fat itself is lower, GGT is lower, alcohol-associated liver disease is very low, and serum albumin is favourable. So this is mixed, not a blanket liver warning.

A useful angle is two useful hooks: PNPLA3 and other DNA differences can explain why some people with modest weight or even lean builds develop fatty-liver risk; and early MASLD is often reversible if the metabolic drivers are changed. That makes this a good "measure and steer" trait rather than a doom trait.

For this sample, this finding can connect the liver area back to the main heart-and-metabolism pattern. If measured triglycerides, HbA1c/glucose, liver enzymes, waist trend, and imaging are quiet, this score becomes context. If they line up, it becomes a practical target.

Cortisol is often flattened into "the stress hormone," but the more useful story is timing. A healthy cortisol rhythm usually has a clear morning rise, then gradually falls through the day so the evening can become sleep-compatible.

Sample Customer's cortisol score is around the 31st percentile, which is lower context rather than a disease signal. It may be relevant beside evening-leaning chronotype, mild daytime sleepiness, and fatigue context, but it is not the same as a measured hormone result.

The best plain-English angle is the morning-light link: early outdoor light helps anchor the cortisol awakening response and the circadian day. That is useful because it connects cortisol to something concrete without pretending the DNA result tells us Sample Customer's actual daily curve.

For this sample, if morning alertness, energy dip, stress load, or sleep timing matter, the useful next layer is rhythm tracking: wake time, light exposure, caffeine timing, exercise timing, evening light, and measured cortisol only if in practice relevant.

AST is less specific than ALT. It can come from liver, muscle, heart, red blood cells, and other tissues, which makes it a useful but slightly slippery biomarker. A higher AST tendency is not automatically a liver story.

Sample Customer's AST score is around the 68th percentile, so the inherited tendency is somewhat higher. That deserves to be shown, but calmly. ALT is near typical, GGT is reassuring, and serum albumin is favourable, so This is not a simple "liver enzymes are genetically high" pattern.

A good practical angle: the AST/ALT pattern can be more informative than either number alone. In metabolic liver disease, alcohol-related patterns, muscle injury, medication effects, and chronic liver disease, the ratio and the surrounding markers can change the interpretation completely.

For this sample, if AST is high in a real blood panel, the next question is not just "liver?" It is: what is ALT doing, what is GGT doing, was there recent hard training, is CK elevated, are platelets or scarring scores abnormal, and is the result persistent?

Chronotype is the body's preferred timing: when alertness tends to arrive, when sleepiness feels natural, and how easily the system locks onto an early schedule. It is partly genetic, but it is also one of the most trainable traits here because light is such a strong clock signal.

Sample Customer's chronotype score is around the 32nd percentile for morningness, so the useful next step is to call this a little more evening-leaning than morning-leaning. That is a good Just interesting finding because it is recognisable and non-medical: it may show up as later alertness, less natural early-morning ease, or more sensitivity to late light and late work.

The best plain-English angle is the phase-response curve idea. Morning outdoor light tends to advance the clock, while evening light tends to delay it. That makes chronotype feel less like a personality trait and more like a system that can be nudged.

For this sample, the practical read is not "you are doomed to be a night owl"; it is "your DNA leans a little later, so light timing, wake timing, meal timing, and screens may matter more."

Creatine kinase is a muscle-stress marker. It can rise after hard eccentric training, muscle injury, some medications, or unusual muscle membrane stress. It is useful precisely because it is dynamic: timing and symptoms matter.

Sample Customer's creatine kinase score is around the 68th percentile, so it is mildly higher context. It is not muscle damage. It is better used as a note that CK, soreness, training load, and recovery can be interpreted together if measured.

A useful statin-myopathy and exercise-damage point: The safe, interesting point is that CK can help distinguish ordinary training response from more concerning muscle breakdown when interpreted properly.

For this sample, it pairs with strength and VO2max planning: progress loading gradually, track recovery, and interpret any measured CK with exercise timing.

Liver fat is where the simple version of fatty liver starts: fat accumulating inside liver cells. It can be driven by insulin resistance, body-fat distribution, alcohol, medications, diet pattern, and specific variants such as PNPLA3 or TM6SF2.

Sample Customer's liver-fat score is around the 33rd percentile, which is reassuring. That is a useful counterweight because nonalcoholic fatty liver disease is higher at around the 70th percentile. The right read is not "fatty liver genetics are uniformly high." It is more nuanced: direct liver-fat tendency looks lower, while broader MASLD/NAFLD susceptibility looks somewhat higher.

An interesting lean-MASLD angle: some people develop liver fat or progress despite not fitting the obvious weight stereotype, because genes like PNPLA3 can change liver handling of fat and scarring. For this sample, BMI genetics are lower and lean-mass context is favourable, so that nuance is worth understanding.

For this sample, this is reassuring, but it does not erase the broader liver context. Measured liver enzymes, FibroScan or liver-fat MRI if in practice relevant, glucose/triglyceride context, and alcohol pattern would decide whether the DNA signal is visible.

Restless legs syndrome is not just fidgeting or ordinary leg cramps. The classic pattern is an urge to move the legs, worse at rest and in the evening, relieved by movement, often disrupting sleep. The interesting biology sits around dopamine, circadian timing, and brain iron handling.

Sample Customer's RLS score is around the 33rd percentile, which is reassuring. Combined with insomnia at <10% category, the genetic layer does not point toward classic sleep-onset insomnia or restless-leg sleep fragmentation as the main sleep story.

A strong clinical nuance: RLS can relate to brain iron even when ordinary blood markers look less dramatic, and dopamine agonists can cause augmentation over time. That is useful credibility material, but Sample Customer's inherited tendency is not high.

For this sample, if leg symptoms exist, the route is symptom-led and measured: ferritin/iron studies, medication triggers, kidney context, pregnancy context where relevant, and sleep disruption pattern.

Sleep efficiency is the percentage of time in bed that is actually spent asleep. It is a useful counterweight to sleep duration because someone can spend a long time in bed but sleep poorly, or sleep a bit less but very efficiently.

Sample Customer's sleep efficiency score is around the 67th percentile, and higher is favourable here. That is reassuring beside the very low insomnia score. It suggests the DNA layer is not pointing toward fragmented, inefficient sleep as a leading problem.

The simple read is this: duration, efficiency, and restedness need to be understood together.

For this sample, if fatigue or daytime sleepiness is present, the next question is not only "how many hours?" but "how consolidated, regular, and restorative?"

BMI genetics are often misunderstood. A many tiny DNA score does not say "you will be this weight"; it says something closer to how sensitive the system may be to the surrounding food, sleep, movement, and stress environment. The interesting finding from obesity genetics is that unhealthy environments amplify genetic differences, while healthier environments can blunt them.

Sample Customer's BMI score is around the 34th percentile, so the inherited tendency is lower than average. That is reassuring, and It matters because there are a much louder glucose-lipid pattern: type 2 diabetes >90th, HbA1c >90th, LDL >90th, ApoB 78th, and triglycerides 77th.

The practical reading is that Sample Customer's heart-and-metabolism signal is not simply a weight story. The DNA layer is pointing more toward glucose handling, lipid particles, and metabolic chemistry than toward a strong inherited tendency for higher body mass. That makes body composition, waist, measured lipids, and glucose markers more informative than BMI alone.

The supporting evidence also flags a useful misconception: DNA-matched diets have not clearly beaten straightforward calorie restriction for weight loss. The more interesting personalised angle is not "which named diet matches your DNA result?" but "which environment makes the inherited tendency matter less?"

Total IgE is a measurable allergy-related immune marker. It is best understood as "allergy volume" rather than an allergy list. It can rise with eczema, asthma, allergic rhinitis, parasites, smoking, ancestry context, and specific sensitisation, but it does not tell you by itself whether milk, dust, cats, mould, or pollen is the problem.

Sample Customer's total IgE score is around the 66th percentile, so it is mildly higher context. That fits with allergic rhinitis in the >90% category and asthma at around the 75th percentile, but it is not the main allergy finding by itself.

The useful idea is directness: unlike many genetic-score findings, IgE is something you can actually measure. A inherited tendency toward higher IgE becomes more meaningful when paired with symptoms and lab context.

For this sample, if allergy symptoms are real-world relevant, the useful route is not total IgE alone; it is pattern plus testing: seasonal triggers, dust/mould/pet exposure, specific IgE or skin-prick testing, asthma symptoms, and treatment response.

Food allergy genetics are often misunderstood. The interesting point is that specific allergies are not inherited like a single family label. A parent having a peanut, shellfish, medication, or venom allergy does not mean a child has inherited that exact allergy. What can be inherited is the broader tendency toward barrier dysfunction and allergic sensitisation.

Sample Customer's food allergy score is around the 35th percentile, which is reassuring. It does not rule out a real allergy if there is a clear reaction history, but the DNA layer is not pointing to food allergy as a main inherited gut or immune story.

The best plain-English angle is the dual-exposure idea: inflamed skin exposure may promote sensitisation, while early oral exposure can help tolerance in some contexts. That makes food allergy feel less like a mysterious single trigger and more like barrier biology plus immune timing.

For this sample, this finding is not a reason to introduce, avoid, or challenge specific foods without the right clinical context. It is a calm inherited-tendency finding, not an allergy test.

Lactate is not metabolic waste. It is fuel, signal, and feedback from the edge between glycolysis and mitochondrial oxidation. In exercise physiology, lactate dynamics can say a lot about metabolic flexibility and training state.

Sample Customer's lactate score is around the 35th percentile, which is lower context. It is not a major finding, but it is interesting beside lower VO2max and higher muscle-mass/strength context because it sits in the exercise-capacity and mitochondrial-efficiency neighbourhood.

The right modern correction: lactate is part of the lactate shuttle and can be adaptive. Zone 2 and high-intensity work train different pieces of the same system.

For this sample, the useful question is not a static lactate result; it is how lactate behaves during graded exercise, training, and recovery.

Urticaria is the hives finding: transient raised wheals, itch, histamine, mast cells, triggers, infections, stress, painkillers, and sometimes autoimmune ways it works. Chronic urticaria can feel mysterious because it often appears without a clean external allergen.

Sample Customer's urticaria score is around the 36th percentile, which is reassuring. This matters because allergic rhinitis and asthma are higher. The allergy-airway story is active, but the inherited hives tendency itself is not.

The most useful angle is that hives are often mast-cell weather rather than a simple "I am allergic to X" story. Allergy, infection timing, stress, medications, temperature, pressure on the skin, and autoimmunity can all change the pattern, but this particular finding does not look like a main Sample Customer signal.

For this sample, if hives occur, symptom history still drives the route: duration, triggers, wheal timing, angioedema, medication exposures, infection timing, thyroid/autoimmune context, and response to antihistamines.

Glycine is one of the nicer sleep-chemistry stories because it is not framed as sedation. The interesting way it works is temperature: glycine appears to help the body move toward the core-temperature drop that naturally gates sleep onset.

Sample Customer's glycine score is around the 63rd percentile, so this is mild context rather than a loud finding. It sits well beside the sleep-chemistry signals, but it is not a need for glycine or proof of a sleep problem.

The best plain-English angle is the "thermostat" framing: glycine may act through the suprachiasmatic nucleus, the brain's master clock, and support peripheral cooling rather than simply knocking someone out. That is more interesting than generic supplement talk.

For this sample, it can help explain why body temperature, evening timing, room temperature, meals, and wind-down routines matter for sleep onset. Practical decisions come from symptoms and response, not the DNA alone.

Daytime sleepiness is not laziness. It can come from sleep debt, circadian mismatch, inflammation, apnea, light timing, caffeine timing, mood, medications, blood sugar swings, or simply asking an evening-leaning body to perform too early.

Sample Customer's daytime sleepiness score is around the 62nd percentile, so it is mildly higher but not a dramatic signal. It becomes interesting because chronotype leans later and fatigue is high elsewhere. The combined story is more useful than the percentile alone: timing and alertness may be worth watching.

A good mismatch angle: genetic chronotype and sleep-need differences can collide with modern schedules. Some people carry rare short-sleep DNA differences, but most daytime sleepiness is debt, timing, or disrupted rhythm rather than a heroic ability to need less sleep.

For this sample, it can invite practical tracking: sleep duration, wake consistency, morning light, caffeine cutoff, alcohol, exercise timing, daytime dips, naps, and whether sleepiness improves with sleep extension.

Memory-performance DNA result is easy to overstate, so the interesting point is actually restraint. Cognitive traits are deeply many tiny genetic nudges, heavily environment-shaped, and current genetic-score models usually explain only a small fraction of real-world variation. Sleep, stress, education, attention, vascular health, mood, exercise, and testing context often matter more day to day than the score itself.

Sample Customer's memory performance score is around the 62nd percentile, which is mildly favourable context. The interesting comparison is reaction time: that score is lower, but for a time measure lower points toward shorter, faster reaction time. So the cognition story is not "good" or "bad"; it is a mixed little pattern, with memory slightly above average and reaction speed looking quicker.

The strongest practical story is DNA result limitations and standards: many genetic-score models have modest predictive power, performance drops across ancestries, and cognitive/memory scores are especially vulnerable to over-interpretation. That is worth saying plainly, because it keeps the finding credible.

For this sample, the natural phrasing is: memory-performance genetics look a little better than average, and reaction-time genetics look faster, but this is curiosity context, not a verdict on cognition.

Achilles tendon injury is mostly about load meeting tissue capacity: sudden training spikes, sprinting, jumping, calf strength, tendon stiffness, footwear, surfaces, age, and prior tendinopathy. Genetics may influence collagen quality and tendon resilience, but training load is usually the louder lever.

Sample Customer's Achilles tendon injury score is around the 61st percentile, so this is only mildly higher. It is more useful as a slow-adaptation reminder than as a major weakness, especially if aerobic or strength training is being ramped.

The strongest practical story is biomechanics and rising sport-related rupture incidence, with genetics as a quieter layer. The useful insight is contralateral and recurrence risk after a real injury, not broad alarm from a modest DNA result.

For this sample, the practical context is progressive calf loading, warm-up, sprint/jump volume, footwear/surface changes, and avoiding abrupt jumps in intensity.

Atopic dermatitis is the eczema and skin-barrier part of the atopy story. It is not just "dry skin." The more interesting biology is barrier plus immune response: filaggrin, lipid layers, irritant exposure, allergen entry, itching, sleep disruption, infection risk, and type 2 inflammation.

Sample Customer's atopic dermatitis score is around the 61st percentile, so it is mildly higher but not especially loud. It fits the allergy cluster because allergic rhinitis is very high and asthma is higher, but eczema itself is quieter.

A useful hook: FLG loss-of-function DNA differences can be unusually strong for a common complex trait because they damage the physical barrier. That makes atopic dermatitis feel concrete. A leaky skin barrier gives allergens a route in.

For this sample, if there is eczema, dry/itchy skin, hand dermatitis, fragrance/soap sensitivity, or childhood atopy history, the finding has practical context. If not, it can stay as background to the stronger airway-allergy story.

Glutamine is a useful bridge molecule: gut barrier support, immune fuel, nitrogen handling, and precursor biology around glutamate and GABA. It is often discussed in muscle or gut contexts, but here it is most interesting as part of the sleep-chemistry chain.

Sample Customer's glutamine score is around the 61st percentile, so it is mildly higher context. It is less distinctive than glutamate, but it helps round out the glutamate/GABA and gut-brain story.

The noisier version of this topic leans into the "gut demand" idea: if the gut is under stress, glutamine demand may change, and that can be discussed in relation to downstream brain-chemistry balance. That is interesting, but a chemistry clue DNA result is not the same as a measured blood level or a proven need for supplementation.

For this sample, the useful read is background: glutamine/glutamate signals suggest sleep chemistry and gut-brain context may be worth understanding, while practical decisions come from symptoms, diet, sleep pattern, gut pattern, and measured data if needed.

Hand grip is not just about hands. It is a cheap proxy for whole-body strength, neuromuscular function, frailty resistance, and training status. It also has the virtue of being easy to measure repeatedly.

Sample Customer's hand grip strength score is around the 61st percentile, which is modestly favourable. Combined with appendicular lean mass at 81st, this supports the "strength/body-composition assets" story.

A useful upgrade: power may be even more prognostic than static strength, because the ability to produce force quickly declines earlier. So the interesting version does not stop at grip; it connects strength to power, balance, and function.

For this sample, it is one of the tangible findings that makes the movement area feel encouraging rather than only risk-focused.

Mean corpuscular volume, or MCV, is average red blood cell size. It helps a blood count sort patterns: smaller red cells can point toward iron issues; larger red cells can point toward B12/folate, alcohol, liver context, medication effects, or other causes.

Sample Customer's MCV score is around the 61st percentile, so the inherited tendency is slightly higher and favourable here. Combined with high MCH and favourable hemoglobin, this gives a calm red-cell-size picture rather than a DNA signal for small, iron-restricted red cells.

The useful lesson is that the pattern matters more than the number. Red-cell size, variation, iron studies, B12/folate, and ancestry/family context can completely change the meaning.

For this sample, this helps explain why the low serum iron signal is worth checking properly, but not automatically translating into a red-cell problem without the actual blood count.

Acetylcarnitine C2 is a small chemistry clue tied to mitochondrial energy handling, acetyl-group shuttling, fatty-acid oxidation, fasting/ketosis state, and exercise metabolism. It is the kind of marker that sounds more actionable than it currently is.

Sample Customer's acetylcarnitine C2 score is around the 60th percentile and is treated as a background clue. That is mild. It is background rather than a health-priority signal.

This is still early as a DNA-reporting story. Acylcarnitines are real and chemistry testing is useful, but a C2 DNA result is not the same as a measured chemistry clue result. The best story is not "take carnitine"; it is that DNA can lightly colour mitochondrial and metabolic-flexibility traits that are otherwise better assessed by real-world markers and response to exercise, fasting, sleep, and diet.

For this sample, if fatigue or exercise recovery is the topic, serum iron, magnesium, sleep, glucose, and training load are much more practical than acetylcarnitine C2.

Betaine is interesting because it is one of the body's backup tools for handling homocysteine. It also sits downstream of choline, which makes these two findings more interesting together than separately.

Sample Customer's score is around the 40th percentile. That is not a major finding, but it points in the same general direction as the much lower choline result. It is not a reason to make a big betaine claim from DNA alone.

The noisy version of this topic can turn into alphabet soup. The calmer version is simpler: betaine is one of the body's nutrient-recycling tools, and measured homocysteine or chemistry testing is a better way to know whether the system needs attention.

For this sample, it becomes more meaningful only if paired with choline, B vitamins, homocysteine, liver context, diet pattern, or symptoms that make this chemistry worth measuring.

DHA is the omega-3 that feels most like a brain-and-retina molecule. It is built into neural and retinal membranes, affects membrane fluidity and signalling, and is often discussed in the context of neuroprotection, vision, pregnancy, and inflammation resolution.

Sample Customer's score is around the 60th percentile, which is mildly favourable. It is not a high-confidence nutrient-status result, but it does mean the DHA-specific DNA signal is not the concern in this omega-3 pair.

A useful bit of colour: DHA is not just "fish oil"; it is discussed as structural membrane material, especially in brain and retina, while FADS genetics can affect conversion from plant ALA into long-chain omega-3s. The careful version is that direct intake and measured omega-3 status are more useful than assuming conversion is adequate.

For this sample, the more practical omega-3 follow-up would be an omega-3 index or diet review, especially because EPA is lower while DHA is slightly favourable.

Ferritin is often described as iron storage, but that is only half the story. It also rises with inflammation, infection, liver disease, and metabolic stress, which is why ferritin can look "fine" or high even when usable iron is not straightforward.

Sample Customer's ferritin score is around the 40th percentile, where lower is treated as less favourable here. By itself that is mild. It becomes more relevant because serum iron is in the <10% category and fatigue is higher. It is not useful to diagnose iron deficiency from DNA, but it can make iron studies feel like a sensible reversible-basic check.

This can stay modest, but there is a useful warning: ferritin is not a clean fuel gauge. Low ferritin can indicate low stores; high ferritin can indicate inflammation or overload; and hepcidin can trap iron in storage while circulating iron stays low. So ferritin needs transferrin saturation, serum iron, iron-binding capacity, CRP/inflammation context, and blood count markers.

For this sample, this is a practical context note. It supports checking ferritin with transferrin saturation rather than guessing from fatigue or serum iron alone.

Platelets are the clotting and repair cells of the blood. They respond to inflammation, infection, iron status, bleeding, medications, spleen function, and marrow signalling, so measured platelet count can move for plenty of non-genetic reasons.

Sample Customer's platelet count score is around the 40th percentile, which is mildly lower in this direction model. On its own, that is not a louder signal. It becomes calmer when placed beside very low venous thromboembolism genetics and Factor V Leiden not detected. The broader clotting picture is not loud.

There is not much plain-English platelet-count genetic-score discussion, so the practical version is the useful one. Platelet count is useful in a blood count pattern, especially with inflammation, iron deficiency, bleeding/bruising symptoms, medication context, or liver/spleen clues. It is not a standalone optimisation target.

For this sample, this is a small background. If a measured platelet count is normal, the DNA result is mostly trivia; if it is low or high, the symptom pattern matters more than the percentile.

Stool frequency sounds mundane, but it is one of the more practical readouts of gut transit. It sits between motility, gut microbes ecology, meal timing, stress physiology, hydration, fibre type, and the nervous system. In research, it is often used as a simple proxy for how quickly the gut moves.

Sample Customer's stool-frequency score is around the 60th percentile, so it is only mildly higher and treated as context. That is interesting because constipation is much higher at in the >90% category. The result does not mean "frequent stools" on its own; it is more useful as part of the broader motility picture.

The best plain-English angle is the ecosystem angle: transit time can shape gut microbes more than people expect. Slow and fast extremes can both change diversity and fermentation, which helps explain why the same food, fibre, or probiotic can feel completely different in different people.

For this sample, this is not a diagnosis; it is a reason to track the ordinary stuff if gut symptoms matter: frequency, Bristol stool type, urgency, bloating, straining, meal timing, sleep, travel, stress, and medication changes.

Total testosterone is easy to overread because the number sounds definitive. It is not. Total testosterone includes bound and unbound hormone, and the same total level can mean different things depending on SHBG, sleep, body composition, illness, inflammation, medications, alcohol, training load, and time of day.

Sample Customer's score is around the 40th percentile, a mild lower-leaning tendency. That is not a dramatic result, and it is not a "low T" diagnosis from DNA. It is a small hormone-axis background clue.

The most useful angle from the context is that testosterone is often an upstream-system readout, not just a gonad readout. People talk about gut inflammation, insulin resistance, poor sleep, overtraining, alcohol, and chronic stress because the body can downshift reproductive signalling when the wider system looks strained.

For this sample, the higher SHBG finding makes it especially important not to infer free testosterone from total testosterone genetics alone.

Fasting glucose is a snapshot: what the blood sugar looks like after not eating. It is useful, but it can miss the rest of glucose biology. Some people have normal fasting glucose and still show big post-meal spikes, high fasting insulin, or early insulin resistance. Others have a slightly high fasting number because of dawn phenomenon, stress, poor sleep, or lab timing.

Sample Customer's fasting-glucose score is around the 41st percentile, so this particular inherited tendency is not high. That is reassuring, but it sits next to type 2 diabetes >90th and HbA1c >90th. The result is not a neat single story. It suggests the glucose cluster may be more about broader diabetes liability, HbA1c biology, insulin response, or post-meal handling than fasting glucose alone.

The useful angle is that thinness and normal fasting values do not always equal metabolic immunity. Family history, genetics, HbA1c, fasting insulin, OGTT, and CGM can reveal different parts of the system. For this sample, this finding helps refine the question: if measured fasting glucose is calm, does HbA1c or post-meal glucose still show anything worth knowing?

Vitamin E is one of the better examples of why nutrient genetics can be interesting without being decisive. Alpha-tocopherol is fat-soluble, travels with lipids, and helps protect cell membranes and polyunsaturated fats from oxidation. That means measured status can depend on diet, absorption, lipid levels, oxidative stress, and supplement form.

Sample Customer's score is around the 42nd percentile, which is only mildly lower. This does not mean "low vitamin E" from DNA. It is a light context: if nutrient status were being checked seriously, measured alpha-tocopherol, lipid adjustment, diet pattern, supplement use, and fat absorption would matter much more.

A useful nutrigenomics angle: people can respond differently to the same micronutrient input. Some vitamin E discussions focus on variants that may change inflammatory response to supplementation, which is exactly why the useful move is "measure and contextualise" rather than "take more".

For this sample, it can add texture to the nutrient area, especially next to omega-3 traits, because vitamin E helps protect fatty acids in membranes from oxidative damage.

Sleep apnea is not just loud snoring or weight. It can involve airway anatomy, craniofacial structure, nasal obstruction, neuromuscular airway control, sleep stage, alcohol or sedatives, age, sex, and metabolic context.

Sample Customer's sleep apnea score is around the 58th percentile, so it is only mildly higher. That matters because snoring is lower at 29th and sleep efficiency is somewhat favourable. The genetic layer does not scream obstructive sleep apnea, but it does justify keeping the airway checklist in the background if symptoms match.

A useful heterogeneity point: apnea severity is not fully captured by one number like AHI, and people can arrive at similar sleep disruption through different routes. That is why symptoms and measurements matter more than DNA alone.

For this sample, it becomes relevant if there is witnessed breathing pause, gasping, morning headache, dry mouth, resistant daytime sleepiness, high blood pressure, or oxygen dips on a wearable.

Vitamin C is familiar, but the biology is not boring. Humans lost the ability to make vitamin C, so intake matters, and ascorbate supports collagen hydroxylation, iron handling, antioxidant cycling, immune function, and tissue repair.

Sample Customer's score is around the 42nd percentile, which is mildly lower but not a deficiency result. It is a context: if status mattered, recent intake, smoking, illness, stress load, gut absorption, plasma vitamin C, and urinary excretion would be more useful than the DNA alone.

A useful way it works: scurvy is not simply "no collagen"; it is failed collagen stabilisation because vitamin C keeps the hydroxylation machinery working. There are also more debatable points about vitamin C forms and animal foods, but those are background rather than the personal story.

For this sample, it is light nutrient colour, not one of the louder signals.

Retinol is active vitamin A, and it is more interesting than "eat carrots". Preformed retinol from animal foods bypasses conversion steps, while plant carotenoids need enzymes, fat absorption, liver handling, transport proteins, zinc, protein status, and inflammation context to become useful vitamin A.

Sample Customer's score is around the 56th percentile, which is slightly favourable and basically quiet. This does not point to a vitamin A concern. If vitamin A status ever mattered, the better layer would be diet form, liver context, serum retinol, retinol-binding protein where relevant, inflammation, and symptoms such as night-vision or skin changes.

A useful measurement caveat: serum retinol can be misleading because transport depends on retinol-binding protein, which itself depends on protein, zinc, liver, and inflammatory context. That makes vitamin A a good example of why a nutrient blood marker is not always a simple tank gauge.

For this sample, the vitamin A picture looks ordinary-to-favourable while the BCO1 conversion marker is absent or not weighted for Sample Customer.

Vitamin B6 is a cofactor vitamin with range: amino-acid metabolism, neurotransmitter synthesis, heme synthesis, transsulfuration, and homocysteine handling. It is also one of the nutrient findings where form matters, because pyridoxine and active active B6 are not the same practical experience for everyone.

Sample Customer's score is around the 56th percentile, which is slightly favourable and basically reassuring. It does not point to a B6 issue.

The most interesting warning here: high-dose synthetic pyridoxine can sometimes create a paradoxical problem, where people take more B6 yet develop neuropathy-like symptoms or functional imbalance. That is not an Sample Customer finding, but it is useful plain-English explanation because it makes the finding feel real rather than like a generic vitamin list.

For this sample, if B6 ever mattered, plasma PLP, supplement dose/form, medication history, neuropathy symptoms, and B2/magnesium/zinc context would be more useful than the DNA alone.

Celiac disease is an autoimmune response to gluten that damages the small intestine. It is heavily shaped by HLA-DQ2/DQ8, but carrying risk HLA is common and most carriers never develop the disease. That gap between risk and disease is the interesting part.

Sample Customer's celiac disease score is around the 45th percentile, which is broadly reassuring. It matters because the gut area is otherwise loud for IBS, ulcerative colitis, and broader IBD. Celiac does not appear to be the main inherited gut story.

A useful angle is a genuinely interesting immunology point: HLA-DQ2.5 may help pre-shape a T-cell repertoire that can recognise gluten before gluten exposure becomes in practice relevant. That is a good science story, but for Sample Customer the result itself is not high.

For this sample, this finding can calm gluten-autoimmunity concern without dismissing symptoms. If there are classic symptoms, family history, iron deficiency, unexplained nutrient issues, or persistent GI symptoms, measured TTG IgA plus total IgA is the right route. DNA alone is not a reason to remove gluten.

Hematocrit is the fraction of blood volume taken up by red blood cells. It is close to hemoglobin biologically, but it is also affected by hydration, altitude, training, smoking, testosterone exposure, inflammation, and iron availability.

Sample Customer's hematocrit score is around the 55th percentile, which is basically typical and slightly favourable here. That helps prevent the iron/fatigue area from sounding uniformly low. Serum iron is low and ferritin is mildly lower, but hematocrit genetics are not pointing toward a low red-cell-volume tendency.

The plain-language point is simple: hematocrit only makes sense inside a complete blood-count pattern, not as a standalone DNA story.

For this sample, if fatigue or iron questions come up, the real blood count matters: hematocrit, hemoglobin, red-cell size, red-cell hemoglobin, red-cell variation, and follow-up markers if needed.

ALT is one of the enzymes people often associate with "liver damage," but it is better treated as a pattern marker than a verdict. It tends to be more liver-specific than AST, yet a normal ALT does not rule out chronic liver disease, fatty liver, or scarring.

Sample Customer's ALT score is around the 46th percentile, which is close to typical and slightly reassuring. That is useful because several liver-background clues are more active: SERPINA1 marker detected, nonalcoholic fatty liver disease around the 70th percentile, chronic liver disease/advanced liver scarring around the 77th, and alkaline phosphatase around the 66th.

The interesting point here is the measurement trap. People can over-interpret a single ALT result, but doctors read it with AST, GGT, bilirubin, albumin, platelets, medication context, alcohol, metabolic health, and sometimes liver stiffness testing. The ratio and the trend often matter more than the isolated number.

For this sample, ALT is not a louder signal. It says the inherited ALT tendency itself is not especially high, while the wider liver picture still deserves a measured panel if this is being followed up.

Omega-3 percentage is the broad fatty-acid readout behind the more specific EPA and DHA findings. It is useful because it combines what someone eats, how well they convert plant ALA, how much omega-6 is competing for enzymes, and how fatty acids end up incorporated into blood or cell membranes.

Sample Customer's score is around the 46th percentile, which is just a mild lower-leaning signal. This does not mean omega-3 deficiency. It is context for a simple, measurable question: what is the actual omega-3 index?

One practical point: plant ALA from flax, chia, or walnuts does not reliably convert into much EPA or DHA for everyone. That does not make plant foods useless, but it does mean direct marine or algal EPA/DHA intake is the cleaner way to raise the measured index.

For this sample, it can be paired with EPA 29th, DHA 60th, and omega-6 >90% rather than interpreted alone.

Riboflavin is the vitamin behind the bright-yellow-urine joke, but the better story is that B2 helps enzymes do their work. One of those jobs sits near folate and homocysteine handling, which is why this finding belongs near the nutrient recycling-style nutrients rather than as a random vitamin fact.

Sample Customer's score is around the 46th percentile, which is near typical and not a B2 concern. It matters mainly as supporting context: if measured homocysteine were high, B2 status could be one of the simple things worth checking.

A useful practical detail: riboflavin is one reason the MTHFR conversation is bigger than one gene or one supplement. Folate, B12, B6, B2, diet, kidney function, thyroid context, and measured homocysteine all change the picture.

For this sample, the practical check, if needed, is not urine colour; it is diet, homocysteine, B-vitamin context, and measured markers where available.

Folate is the B-vitamin that made internet genetics famous, mostly because of MTHFR. The calmer truth is less dramatic: folate helps with cell renewal and homocysteine handling, but it only makes sense alongside B12, B6, B2, diet, medicines, alcohol, and real blood markers.

Sample Customer's score is around the 53rd percentile, which is basically typical. This does not point to a folate-specific inherited concern. If folate status mattered, measured folate, B12 markers, homocysteine, diet, medication history, and alcohol intake would be more informative than DNA alone.

A useful misconception: folic acid, food folate, and methylfolate are not identical molecules in the body. But it is easy to overstate MTHFR folklore. Many people with common MTHFR patterns maintain normal homocysteine when folate, B12, riboflavin, and overall diet are adequate.

For this sample, the point is not "folate is low"; it is "folate genetics looks ordinary, so the homocysteine signal is better checked functionally rather than explained away by folate alone."

Non-HDL cholesterol is a simple but useful calculated marker: total cholesterol minus HDL. It captures the cholesterol carried by artery-risk particles, including LDL, VLDL remnants, IDL, and Lp(a). It is often more informative than total cholesterol and, in many contexts, easier to interpret than LDL alone.

Sample Customer's non-HDL score is around the 53rd percentile, so the inherited tendency is close to typical. That is interesting because LDL cholesterol is much higher genetically, while ApoB and triglycerides are moderately above average. It suggests the lipid story is not simply "all cholesterol measures are high"; it is more specific.

Non-HDL gets less attention than ApoB or Lp(a), which makes sense. It is not glamorous, but it is practical. A standard lipid panel gives you the number, and it helps capture remnant-rich or mixed lipid patterns that LDL-C alone can miss.

For this sample, non-HDL helps complete the lipid stack while keeping priority on measured ApoB, LDL-C, triglycerides, and Lp(a).

Serum urate is the measurable uric-acid finding. It matters because urate handling connects gout, kidney function, metabolic health, alcohol, fructose, diuretics, and crystal-driven joint inflammation.

Sample Customer's serum urate score is around the 53rd percentile, which is basically typical. That is useful nuance because gout DNA result is moderately higher. This does not imply that Sample Customer has a strong inherited tendency to high serum urate from this finding alone.

A good evolutionary hook: humans lost functional uricase, so we run higher urate than many mammals. That makes urate a trade-off molecule: possibly useful in some contexts, problematic when levels, kidney handling, and crystals line up badly.

For this sample, if gout or urate matters in real life, measured serum urate, kidney function, beer/fructose intake, metabolic context, and flare history are the important layer.

TMAO is one of those chemistry clues that became famous because it links food, microbes, liver enzymes, and cardiovascular risk. Gut bacteria convert choline and carnitine from foods such as eggs and red meat into TMA, and the liver converts TMA into TMAO. But the story is not simply "TMAO bad"; context, kidney function, diet, gut-microbe mix, and even cancer-immunology models complicate the picture.

Sample Customer's TMAO score is around the 48th percentile, which is basically typical. That means this finding cannot be used to intensify the already-loud heart-and-metabolism area. LDL, ApoB, HbA1c, type 2 diabetes, and triglycerides are doing the real work there; TMAO is not.

One properly interesting twist: the same molecule discussed in cardiovascular-risk threads has also shown potentially helpful immune effects in some cancer model contexts. That does not make it a action target, but it does stop the finding from reading like a simplistic food scare.

For this sample, this is deep context. If TMAO were ever measured directly, it would need context: recent meals, fish/seafood, kidney function, choline/carnitine supplement use, overall diet pattern, and the broader heart-and-metabolism picture.

Transferrin saturation is the share of iron-carrying capacity actually loaded with iron. It helps separate iron storage, iron transport, inflammation, and whether iron is available to use.

Sample Customer's transferrin saturation score is around the 51st percentile, so the inherited tendency is basically typical. That matters because serum iron is in the <10% category and hepcidin is high. The DNA result is not saying the whole transport system is genetically low; serum iron itself is the more notable finding.

A useful plain-English angle here is the full-panel lesson. Ferritin can rise for reasons that are not simple iron abundance; serum iron moves around; transferrin saturation shows how much of the carrying system is actually loaded. That makes it a better reality check than ferritin alone.

For this sample, if fatigue, low-iron symptoms, restless legs, or performance issues are present, the practical step is to read ferritin, transferrin saturation, serum iron, iron-binding capacity, inflammation markers, and blood count together.

eGFR is the standard estimate of how well the kidneys filter blood. The tricky part is that "estimated" is doing real work: creatinine-based eGFR can be shifted by muscle mass, diet, training, age, illness, and the equation used.

Sample Customer's eGFR score is around the 50th percentile, essentially median. That is important because the kidney story otherwise has one higher signal: albuminuria. The DNA layer is not saying "filtration genetics are poor"; it is saying the leakage marker looks more interesting than the filtration marker.

The best practical point is that albuminuria and eGFR are partly different kidney failure modes. One is more about leakage through the filter; the other is more about filtration capacity. You can have one move before the other, and genetics can separate them too.

For this sample, this finding cannot be dramatic. The practical read is: measured eGFR is still useful, but urine albumin-to-creatinine ratio and cystatin C add meaningful context, especially if creatinine alone looks too tidy or too noisy.